

Covid-19: Conflicts of Interests?

Follow The Money Down The Rabbit Hole

“The pandemic represents a rare but narrow window of opportunity to reflect, reimagine, and reset our world.”

Klaus Schwab

Founder and Executive Chairman, World Economic Forum






World Health
Organization

Conflicts of Interests?

Bill Gates and the World Health Organisation



Top 20 contributors to the Programme budget 2018 (US\$ thousands)



Top 20 contributors to the WHO Programme budget 2018 (US\$ thousands)

Image: World Health Organization



World Health Organization

BILL & MELINDA
GATES foundation

Contribution 10.8% of WHO budget


\$455 million



\$389 million

Contribution 8.8% of WHO budget

World Health Organisation Donors



* Excluded – GAVI 7.9%

Bill Gates and the World Health Organisation



World Health
Organization

Total Contributions:

Country/ Foundation	Total Contribution	Percentage
USA	\$863 million	19.6%
Gates Foundation/ Gavi	\$844 million	18.6%

<https://www.who.int/about/funding/contributors>

Top 20 contributors to the WHO for the 2018/2019 biennium

Contributor	Funding received US\$ million
United States of America	853
United Kingdom of Great Britain and Northern Ireland	464
Bill & Melinda Gates Foundation	455
GAVI Alliance	389
Germany	359
UN Office for the Coordination of Humanitarian Affairs (UNOCHA)	286
Japan	234
European Commission	213
Rotary International	168
National Philanthropic Trust	116
UN Central Emergency Response	100
Kuwait	95
World Bank	95
Norway	93
China	89
Canada	87
Sweden	87
Republic of Korea	72
Australia	71
France	71



CONTRIBUTORS

WHO Contributors	WHO Contributors	
Bill and Melinda Gates Foundation	Johnson & Johnson	*
* GAVI Alliance	Johnson & Johnson Companies Contribution Fund	*
* Wellcome Trust	Gilead Sciences Inc.	*
World Bank	Merck & Co.	*
* COVID-19 Solidarity Fund	GlaxoSmithKline	*
United Nations Development Fund (UNDP)	Sanofi-Aventis	*
United Nations Population Fund	Ely Lilly & Foundation	
CDC Foundation	Bayer AG	
* Gates Ventures	Bristol-Myers Squibb	
Path Vaccine Solutions	Hoffman-La Roche	*
* National Institutes of Health (USA)	Novartis	*
* Program for Appropriate Technology in Health (PATH)		
Sandoz AG		
Sabin Vaccine Institute		
Rockefeller Foundation		
Open Society Foundations		
Clinton Health Access Initiative		
Care International	Period 2020 - 2021	

WHO Funding: Conflict of Interest or Independence in Question?

Drug and chemical industry donations to the WHO

The multinational drug and chemical industries and their investors figure prominently in the lists of WHO donors. Money contributed to the WHO's General Fund by these sources during 2017 included the following:


Bayer AG	\$1,158,060
Bristol-Myers Squibb	\$215,730
Denka Seiken	\$417,324
Eisai	\$280,000
Gilead Sciences	\$3,124,450
GlaxoSmithKline	\$7,365,666
Green Cross Corporation	\$294,582
Hoffman-La Roche	\$6,628,090
Kaketsuken	\$417,324
Merck	\$510,000
Merck Sharp and Dohme Chibret	\$1,652,226
Novartis	\$500,000
Rockefeller Foundation	\$748,945
Sanofi Pasteur	\$9,411,491
Sanofi-Aventis	\$2,634,963

Other prominent WHO donors during 2017 included banks, private foundations with links to the pharmaceutical industry, and the [George Soros Open Society Institute](#).



World Health
Organization


PIP CONTRIBUTIONS





World Health
Organization





ALL IN-KIND / SERVICE CONTRIBUTORS



World Health Organisation: Big Pharma Influence

 World Health Organization	HOME	OUR WORK	BUDGET & FINANCING	REGIONS	CONTRIBUTORS	WHO		 2020-21 
Total In-Kind – Medical supplies and materials Contributions by Contributors 								
United Arab Emirates								10,376K
Johnson and Johnson Family of Companies Contribution Fund, Inc.								10,114K
Merck & Co., Inc.								9,438K
GlaxoSmithKline (GSK)								8,204K
Republic of Korea								5,990K
Novartis								4,796K
Eisai Co., Ltd.								857,684
Johnson & Johnson Consumer Health								760,630
Kobe Group (Hyogo Prefecture Kobe Chamber of Commerce and Industry and Kobe Steel, Ltd.)								674,836
Gilead Sciences Inc.								466,538
Bayer AG								416,873
Cipla Health Ltd.								200,000
Vital Strategies								81,486
EMS S.A. Brazil								37,762
Fondation d'Entreprise Sanofi Espoir								15,586
Chemo Iberica S.A, Spain								1,092
Total								52,431K

World Health Organisation: Big Pharma Influence

 World Health Organization	HOME	OUR WORK	BUDGET & FINANCING	REGIONS	CONTRIBUTORS	WHO		 2018-19
Total In-Kind – Medical supplies and materials Contributions by Contributors 								
Merck & Co., Inc.					35,413K			
GlaxoSmithKline (GSK)					30,862K			
Johnson and Johnson Family of Companies Contribution Fund, Inc.					14,239K			
Eisai Co., Ltd.					10,733K			
Novartis					7,496K			
Gilead Sciences Inc.					1,405K			
Kobe Group (Hyogo Prefecture Kobe Chamber of Commerce and Industry and Kobe Steel, Ltd.)					674,836			
Fondation d'Entreprise Sanofi Espoir					556,878			
Bayer AG					173,974			
Switzerland					77,517			
Total					101,630K			



World Health
Organization

Big Pharma Conflicts of Interests

WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics 2004

Prof. Karl Nicholson, Member of The European Scientific Working Group on Influenza (ESWI), **Prof. Frederick Hayden**, University of Virginia, **Dr. Arnold Monto**, University of Michigan

Prof Nicholson is on the **Roche** pharmaceutical Company Payroll. He conducted a randomised controlled trial on oseltamivir (Tamiflu) supported by **Roche** and also received travel sponsorship and honorariums from **GlaxoSmithKline and Roche** for consultancy work and speaking at international respiratory and infectious diseases symposiums

Prof Hayden paid by **Roche** for lectures and consultancy work for the company at the time the guidance was produced and published, also received payments from **GlaxoSmithKline** for consultancy and lecturing until 2002. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE) and Board of Wellcome Trust

Prof Monto received honorariums, consultancy fees, and research support from **GSK, Novartis, Roche, Baxter and Sanofi, MedImmune**, consultancy fees and research (GlaxoSmithKline, \$3000 speakers fees in 2009) and also research funding from ViroPharma.



Prof. Karl Nicholson



Prof. Fred Hayden



Dr. Arnold Monto



World Health
Organization

&

ESWI

...scientists fighting influenza

Sponsors





World Health
Organization

Big Pharma Conflicts of Interests

Influenza Pandemic Plan: The Role of WHO and Guidelines for National and Regional Planning

R Snacken, J Wood, L R Haaheim, A P Kendal, G J Ligthart, and D Lavanchy

This document was prepared for the World Health Organization (WHO), in collaboration with the European Scientific Working Group on Influenza (ESWI)(1999).

Dr. René Snacken of the Belgian Ministry of Public Health, WHO Division of Viral Diseases wrote about studies involving neuraminidase inhibitors for a **Roche promotional booklet**

Dr Daniel Lavanchy, **appeared at a Roche sponsored symposium in 1998** while employed at WHO Division of Viral Diseases.

Professor Abe Osterhaus, ESWI Chairman, conducted a **randomised controlled trial on oseltamivir (Tamiflu) supported by Roche**. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE)



World Health
Organization

&

ESWI

...scientists fighting influenza

Sponsors



AstraZeneca



Johnson & Johnson



NOVARTIS

sanofi

Baxter



MedImmune



The Corporatization of the WHO: A Question of Independence?



COVID-19 Solidarity Response Fund

FUND SUPPORTERS



Gates Foundation: Decade of Vaccines Collaboration

Global Health Leaders Launch Decade of Vaccines Collaboration | Bill & Melinda Gates Foundation

Media contact

Phone:

206-709-3400 ↗

Mail:

media@gatesfoundation.org →



Decade of Vaccines

Magdalena Robert

Phone: +34 93 227 1806

The Council comprises of the Director-General of the WHO, the Director of NIAID, the Director of UNICEF, the President of Gates Foundation Global Health, and the Chair of the African Malaria Alliance

NEW YORK -- The World Health Organization (WHO), UNICEF, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation have announced a collaboration to increase coordination across the international vaccine community and create a Global Vaccine Action Plan. This plan will build on the successes of current work to achieve key milestones in the discovery, development and delivery of lifesaving vaccines to the most vulnerable populations in the poorest countries over the next decade.




Global Vaccine Action Plan publication

The Global Vaccine Action Plan (GVAP) — endorsed by the 194 Member States of the World Health Assembly in May 2012 — is a framework to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

GVAP was the product of the DoV Collaboration, an unprecedented effort that brought together development, health and immunization experts and stakeholders. The leadership of the Bill & Melinda Gates Foundation, GAVI Alliance, UNICEF, United States National Institute of Allergies and Infectious Diseases and WHO, along with all partners – governments and elected officials, health professionals, academia, manufacturers, global agencies, development partners, civil society, media and the private sector – are committed to achieving the ambitious goals of the GVAP. Many more are expected to add their support in the future as the plan is translated and implemented at the country and regional levels.

BILL & MELINDA
GATES foundation



14 JUNE 2020

**Global Vaccine
Action Plan
Monitoring,
Evaluation &
Accountability:
Secretariat
Annual...**

Download

Read More



Conflicts of Interest

Bill Gates influence invests Big in Big Pharma and Vaccine Industry

BILL & MELINDA
GATES *foundation*

June 4, 2020

**Bill and Melinda Gates
Foundation pledges \$3 billion to
GAVI, The Vaccine Alliance, to
protect the next generation with
lifesaving vaccines**

Whistleblower exposes WHO Corruption

On Vaccines and Immunity

- GAVI operates like a Vaccine Cartel, controlling the coronavirus response of nations. They have 'Total Immunity' from prosecution.
- Bill Gates funded GAVI (Global Alliance for Vaccines and Immunisation) has created a system called "Performance based funding" whereby they financially punish nations based on their compliance or non-compliance to vaccination programs.
- World Bank and GAVI (BMGF funded) created the IFFM International Financial Facility for Immunization. They have an agreement that GAVI receives money from countries. GAVI dictates vaccine policies for countries and countries pay them – HUGE CONFLICT OF INTEREST



Dr Astrid Stuckelberger
WHO Insider and Whistleblower

Bill Gates influence invests in Big in Big Pharma and Vaccine Industry



OUR ALLIANCE

PROGRAMMES & IMPACT

INVESTING IN GAVI

#VACCINESWORK

NEWS & RESOURCES



makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries




Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the **Bill & Melinda Gates Foundation** will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be safe and effective, for low- and middle-income countries in 2021

Vaccine Alliance: Major Conflicts of Interest

Gavi Board Chair: José Manuel Barroso



Fig. José Manuel Barroso, GAVI Chair



The WEF and Major Conflicts of Interest

Gavi Board Chair: José Manuel Barroso



José Manuel Barroso, GAVI Chair, WEF (May, 10, 2010)



Fig. José Manuel Barroso, Klaus Schwab in deep conversation at the World Economic Forum on Europe held in Brussels, Belgium, May 10, 2010.

Vaccine Alliance: Major Conflicts of Interest

Gavi Board Member: Margaret Ann Hamburg



Margaret Ann Hamburg



Assistant Secretary



National Institute of Allergy and Infectious Diseases



Assistant Director



U.S. FOOD & DRUG ADMINISTRATION

FDA Commissioner

BILL & MELINDA GATES foundation

Member of the Global Health Scientific Advisory Committee

CEPI

Chair of the Joint Coordinating Group



The ROCKEFELLER FOUNDATION

Board of Trustees Member

THE ROCKEFELLER UNIVERSITY

Science for the benefit of humanity



HENRY SCHEIN®

Board Director

U.S. distributor of flu vaccines and dental amalgam



Alnylam®
PHARMACEUTICALS

Member of the Board of Directors
RNAi therapeutics

SANOFI

10% share



NOVARTIS

\$545M sharevalue



wellcome

Member of the Strategic Advisory Board on Vaccines and Drug-resistant Infections



BUILDING A SAFER WORLD

Senior Scientist
Nuclear Threat Initiative



AAAS
ADVANCING SCIENCE, SERVING SOCIETY

Chair of the Board



CENTER FOR STRATEGIC & INTERNATIONAL STUDIES

senior fellow

COUNCIL on FOREIGN RELATIONS

Member of the Board of Directors, Independent Task Force on Improving (Covid) Pandemic Preparedness, 2020



Harvard University
Member of the Board of Fellows

Renaissance



Peter Fitzhugh Brown
Hamburg's Husband,
CEO Renaissance



TITAN®
PHARMACEUTICALS

61,913 shares
December 2015

Probuphine

Johnson & Johnson



MERCK



Abbott

medco®



Board of Directors

COUNCIL *on*
FOREIGN
RELATIONS



Margaret (Peggy) Hamburg

Vaccine Alliance: Major Conflicts of Interest

MarketScreener					Members of the board			
Symbol or Keyword(s)					Name	Title	Age	Since
MARKETS	NEWS	ANALYSIS	STOCK PICKS	PORTFOLIOS	Michael Bonney	Independent Director	63	2014
					Phillip A. Sharp, Dr.	Independent Director	76	2002
Delayed Nasdaq - 05/06 04:00:00 pm EDT 134.75 USD -1.46%					Marsha H. Fanucci	Independent Director	68	2010
05/04 Alnylam to Webcast Presenta 05/02 HC Wainwright Adjusts Alnyl 05/02 Berenberg Bank Adjusts Alnyl					Dennis Arthur Ausiello, Dr.	Independent Director	75	2012
Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revis					Amy L. Schulman	Lead Independent Director	60	-
Business Summary					David Pyott	Independent Director	68	2015
 <p>Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STARs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.</p>					Colleen F. Reitan	Independent Director	61	2018
					Margaret A. Hamburg, Dr.	Independent Director	65	2019
					Olivier Brandicourt	Independent Director	67	2020
					Yvonne Greenstreet	Chief Executive Officer & Director	59	2022
Shareholders								
					Name	Equities	%	
					Fidelity Management & Research Co. LLC	13,406,771	11.2%	
					Baillie Gifford & Co.	10,616,751	8.83%	
					The Vanguard Group, Inc.	10,441,860	8.69%	
					Wellington Management Co. LLP	6,844,430	5.69%	
					T. Rowe Price Associates, Inc. (Investment Management)	6,535,368	5.44%	
					Dodge & Cox	5,431,068	4.52%	
					Capital Research & Management Co. (Global Investors)	3,494,656	2.91%	
					SSgA Funds Management, Inc.	2,850,389	2.37%	
					BlackRock Fund Advisors	2,496,485	2.08%	
					JPMorgan Investment Management, Inc.	2,214,127	1.84%	

Scientific Advisory Committee

Our Scientific Advisory Committee comprises a group of esteemed experts from outside of the foundation who offer a wide range of experiences and perspectives. This group plays an important role in strengthening our work by offering independent assessments of our Global Health Division strategies and helping us evaluate results.

Margaret A. Hamburg, M.D.

Margaret A. Hamburg, an internationally recognized leader in public health and medicine, is the foreign secretary for the U.S. National Academy of Medicine and the president of the American Association for the Advancement of Science (AAAS). She is the former commissioner of the U.S. Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. As FDA commissioner, she was known for advancing regulatory science, streamlining and modernizing the FDA's regulatory pathways, and globalization of the agency. Before joining the FDA, Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical, and



Fig. Margaret A. Hamburg, M.D., Member of the Global Health Scientific Advisory Committee

Henry Schein's Margaret Hamburg hired by FDA



On November 3, 2003, Henry Schein, Inc., the largest distributor of mercury-containing amalgam products, announced the appointment of **Margaret A. Hamburg, MD to its Board of Directors**, where she served until she was confirmed as Commissioner of the US Food and Drug Administration (FDA) on May 18, 2009. As of July 27, 2009, however, Dr. Hamburg still held **a financial interest in Henry Schein, including stock options**. On July 28, 2009, the FDA announced a rule on dental amalgam that permitted Henry Schein to sell the product without disclosing its 50% mercury content to consumers. On July 30, 2009, Henry Schein general counsel Michael Ettinger e-mailed Dr. Hamburg thanking her for a service she performed while at FDA and acknowledging Schein was "indebted" to her for this service.

Courtesy: The Outliers

yahoo!finance

Search for news, symbols or companies



Sign in



Finance

Watchlists

My Portfolio

Cryptocurrencies

Yahoo Finance Plus

Screeners

Markets

News

Personal Finance

Videos

Yahoo U

...

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura® technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.



Vaccine Alliance: Major Conflicts of Interest

MarketScreener Symbol or Keyword(s)

MARKETS **NEWS** **ANALYSIS** **STOCK PICKS** **PORTFOLIOS**

TITAN PHARMACEUTICALS, INC. (TTNP)

Delayed Nasdaq - 05/06 03:59:03 pm EDT
0.6689 USD **-5.79%**

05/06 TITAN PHARMACEUTICALS
04/25 Activist Investing Acquires M
04/25 Activist Investing Announce

Summary Quotes Charts News Ratings Calendar **Company** Financials

Business Summary

TITAN PHARMACEUTICALS

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.

Number of employees : 11 people.

Shareholders		
Name	Equities	%
David Elliot Lazar	673,211	5.59%
Sabby Capital LLC	494,716	4.11%
The Vanguard Group, Inc.	204,306	1.70%
Citadel Advisors LLC	68,908	0.57%
Geode Capital Management LLC	53,053	0.44%
Harrow Health, Inc.	51,021	0.42%
Group One Trading LP	44,757	0.37%
GSA Capital Partners LLP	39,820	0.33%
G1 Execution Services LLC	38,930	0.32%
Credit Suisse Securities (USA) LLC (Broker)	23,200	0.19%



Peter Fitzhugh Brown

1. Husband of FDA Commissioner. Margaret Hamburg
2. CEO of Renaissance LCC (Major Shareholder of Titan Pharmaceuticals Inc.)



World Health
Organization

Treachery: Vaccine Hesitancy

INTERNET ARCHIVE
WayBackMachine

<https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019>

Go

JUL AUG SEP

12

2020

2021

163 captures

18 Jan 2020 - 11 Apr 2021



[Home](#) / [Newsroom](#) / [Feature stories](#) / Ten threats to global health in 2019

WHO identifies

Ten threats to global health in 2019

Vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – threatens to reverse progress made in tackling vaccine-preventable diseases. Vaccination is one of the most cost-effective ways of avoiding disease – it currently prevents 2-3 million deaths a year, and a further 1.5 million could be avoided if global coverage of vaccinations improved.



World Health
Organization



global health
workforce
alliance

Global Partners

Search

Global Health Workforce Alliance

About the Alliance

Members & partners

Country responses

Knowledge centre

Media centre

Global Forums

Bill & Melinda Gates Foundation

Member profile

The Bill & Melinda Gates Foundation (Gates) is a funding organization based in Seattle, Washington USA. Guided by the belief that every life has equal value, this innovative group works to help all people lead healthy, productive lives. In particular, this foundation focuses on improving people's health and on giving them the chance to lift themselves out of hunger and extreme poverty. The valuable resources shared help empower people for success.

Main activities

The Bill & Melinda Gates Foundation works with organizations around the world that are using innovative methods to improve healthcare. The main mission is to help ensure that advances in health are created and shared with those who need them most.

The three priority areas are to:

- Develop effective and affordable vaccines, medicines, and other health tools.
- Deliver proven health solutions to those who need them most.



BILL & MELINDA
GATES foundation

Bill & Melinda Gates
Foundation

Develop effective and affordable vaccines, medicines and other health tools

Current SAGE Board Members

N°	Name	Position	First SAGE meeting participated in	Expected last SAGE meeting to be participated in
1	Dr Alejandro Cravioto (Chair)	Affiliated with the Faculty of Medicine of the Universidad Nacional Autónoma de México (UNAM), Mexico	Oct. 2015 (reappointed Jan. 2020)	Oct. 2021 (Chair since Oct. 2016)
2	Prof. Rakesh Aggarwal	Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India	Apr. 2017 (reappointed Jan. 2020)	Oct. 2022
3	Dr Ilesh Jani	Instituto Nacional de Saúde , Ministry of Health, Mozambique	Oct. 2015 (reappointed Oct. 2018)	Apr. 2022
4	Dr Jaleela Jawad	Immunization Manager, Ministry of Health, Bahrain	Apr. 2015 (reappointed Oct. 2018)	Oct. 2022
5	Dr Sonali Kochhar	University of Washington, Seattle	Jan. 2021	Dec. 2023*
6	Prof. Noni MacDonald	Dalhousie University, Canada	Apr. 2017 (reappointed Jan. 2020)	Dec. 2022
7	Prof. Shabir Madhi	University of the Witwatersrand, South Africa	Apr. 2019	Dec. 2021*
8	Prof. Peter McIntyre	University of Otago, New Zealand	Apr. 2019	Dec. 2021*
9	Dr Ezzeddine Mohsni	Global Health Development / Eastern Mediterranean Public Health Network, Jordan	Apr. 2019	Dec. 2021*
10	Prof. Kim Mulholland	Murdoch Children's Research Institute, Parkville	Jul. 2020	Dec. 2022*
11	Dr Kathleen Neuzil	University of Maryland School of Medicine, USA	Apr. 2019	Dec. 2021*
12	Dr Hanna Nohinek	Finnish Institute for Health and Welfare THL, Finland	Jan. 2020	Dec. 2022*
13	Dr Folake Olayinka	USAID (Public Health Institute STAR Fellow)	Jan. 2020	Dec. 2022*
14	Prof. Punnee Pitisuttithum	Mahidol University, Thailand	Jan. 2021	Dec. 2023*
15	Prof. Andrew Pollard	University of Oxford, United Kingdom	Apr. 2016 (reappointed Jan. 2020)	Dec. 2021

Last updated: 4-Feb-2021

*Member may be re-appointed for a second term.

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Alejandro Cravioto (Chair)	Universidad Nacional Autónoma de México, Puerto Vallarta, Mexico	Bill & Melinda Gates Foundation. Wellcome Trust. Chief Scientific Officer of International Vaccine Institute (IVI). Executive Director. International Centre for Diarrhoeal Disease Research (icddr, USAID, NIH. CDC. Global Fund)
Dr Hanna Nohynek (Vice-Chair)	Chief Physician, Finnish Institute for Health and Welfare (Thl), Helsinki, Finland	Bill & Melinda Gates Foundation. PATH. Oxford University on ComCov studies. Grants from EU Commission. Expert adviser to European Medicines Agency. Honoraria for GSK and Pfizer. Finnish Institute for Health and Welfare receives funding from Sanofi Pasteur. GlaxoSmithKline.
Prof Shabir Madhi	Univ of the Witwatersrand, Johannesburg, SA	Funding from Pfizer, Minervax, GlaxoSmithKline, Novavax. Bill & Melinda Gates Foundation. International Vaccine Institute (IVI) Scientific Advisory Committee. BMGF Global Health Scientific Advisory Committee. Advisor to the Pfizer Group B streptococcal (GBS) vaccine program. Member of the DSMB of GSK and Janssen. Chair of the DSMB of CAPRISA. Clinical-Regulatory Advisory Board of CureVac for Covid-19 vaccine. National Principal Investigator, AstraZeneca ChAdOx-nCoV19 vaccine. Wits Health Consortium funded by Novartis, GSK, Medimmune, Novavax. Mitsubishi. Merck (MSD), Novavax.
Prof Peter McIntyre	Dunedin School of Medicine, Univ of Otago, Dunedin, New Zealand	Member of the DSMB for the Novavax Covid-19 vaccine. Member of the New Zealand Scientific and TAG on COVID-19 vaccines. Deputy Director of Australia's National Centre for Immunisation Research and Surveillance of Vaccine-Preventable Diseases (NCIRS). investigator on Wellcome Trust grant.

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Anthony Scott	London School of Hygiene and Tropical Medicine. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya	Funding from Wellcome Trust, Bill and Melinda Gates Foundation, National Institute for Health Research (NIHR). Worked with WHO and GAVI on vaccines. Joint Committee on Vaccination and Immunisation (JCVI) Board member. Director of the NIHR Health Protection Research Unit in Immunisation. Advisor to UK Health Security Agency. World Bank International Vaccines Task Force.
Prof Kathleen M. Neuzil	Director, Univ of Maryland School of Medicine, Baltimore, USA	Funding from Pfizer and NIH. Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021). CDC Advisory Committee on Immunization. Serum Institute of India, Ltd. Co-chair of the NIH COVID Vaccine Prevention Network. Univ of Maryland funding from GSK, Merck, Nosocomial Vaccine Corporation, ICON Clinical Research. Previous employment: PATH. Studied at Johns Hopkins University School of Medicine. Member on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. Associate Editor of the journal Vaccine
Prof Kim Mulholland	Professor of Child Health and Vaccinology, London School of Hygiene and Tropical Medicine. Murdoch Children's Research Institute (MCRI), Melbourne, Australia	Safety Monitoring Committee from the Novavax Covid-19 Vaccine. Novavax Maternal RSV immunization project. PCV13 vaccination project on adult pneumonia in Mongolia funded by Pfizer. Principal Investigator in pneumococcal vaccine trials 1 and 2 funded by the Bill and Melinda Gates Foundation. Member of Gates Foundation DeCoDe Committee to review CHAMPS. Receives funding from GAVI.
Prof Noni MacDonald	Paediatrics, Dalhousie University, Halifax, Canada	Funding from Bill and Melinda Gates Foundation, WHO (Consultancy). Academic Committee Member of Leger, Canada. Board member of International Vaccine Institute. Member of the SAGE Working Group on Vaccine Hesitancy

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Rakesh Aggarwal	Director, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India	MSc from London School of Hygiene and Tropical Medicine
Dr Jaleela Jawad	Consultant, Ministry of Health Manama, Bahrain	CDC USA
Dr Sonali Kochhar	Assoc Prof, Univ of Washington, Seattle, USA	Funding from Bill & Melinda Gates Foundation, Wellcome Trust.
Prof Punnee Pitisuttithum	Mahidol University, Bangkok, Thailand	Safety Monitoring Committee for the U.S. Military HIV Research Program. Principal investigator Safety of Tri Fluvac influenza vaccine and MSD-funded 9vHPV vaccine.
Dr Folake Olayinka	Immunization Team Leader, USAID (Public Health Institute STAR Fellow). Washington, USA	Advisor to the WHO-AFRO Regional Immunization Technical Advisory Group.
Dr Ezzeddine Mohsni	Programme Essaha Aziza, European Union Tunis, Tunisia	Funding from Bill and Melinda Gates Foundation, Gavi and WHO.
Dr Ilesh V. Jani	Director General, National Institute of Health, Marracuene, Mozambique	Funding from CEPI and Bill and Melinda Gates Foundation, Janssen Vaccines & Prevention B.V., US National Institutes of Health (NIH), the HIV Vaccine Trial Network (HVTN). Grant/research support from WHO
Prof Andrew Pollard (former member)	Director of the Oxford Vaccine Group	Chief investigator for the Oxford-AstraZeneca COVID-19 vaccine clinical trials. Chair, Joint Committee on Vaccination and Immunisation (JCVI), Chair Scientific Advisory Group on Vaccines at the European Medicines Agency, National Institute for Health and Care Excellence (NICE, UK). Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, Advisor to the European Medicine Agency (EMA). Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK. Funding from Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),

[Health Topics](#) ▾[Countries](#) ▾[Newsroom](#) ▾[Emergencies](#) ▾[Data](#) ▾[About Us](#) ▾

Strategic Advisory Group of Experts on Immunization, Vaccines and Biologicals (SAGE)



Bernard Fritzell, M.D., M.P.H. former Vice-President, International Scientific and Clinical Affairs, Pfizer Vaccines Research



Barney S. Graham, M.D., PhD Senior Investigator at the Vaccine Research Center, NIAID, NIH



Ruth Karron, M.D. CDC Advisory Committee on Immunization Practices. FDA Vaccine and Related Biological Products Advisory Committee



David C. Kaslow, M.D. Vice President, Essential Medicines, and Head, PATH's Center for Vaccine Innovation and Access Vice President and Head of Vaccines Project Leadership and Management at Merck Research Laboratories National Institute of Allergy and Infectious Diseases (NIAID)



Jerome H. Kim, M.D., Director General of the International Vaccine Institute (IVI) funded by Bill and Melinda Gates Foundation.



Prof. Shabir Madhi, Prof Vaccinology, Wits Univ. Head of SA AstraZeneca ChAdOx1 Trial, Chair of the National Advisory Group for Immunization in South Africa and on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation Global Health Program.



Dr Tedros Adhanom Ghebreyesus Global Elite “Prostitute”




Tedros Adhanom Ghebreyesus: Global Elite “Prostitute”



[Join us](#)

[Sign in](#)



Tedros Adhanom Ghebreyesus

Director-General, World Health Organization (WHO)

PhD in Community Health, University of Nottingham; MSc in Immunology of Infectious Diseases, University of London. Health scholar, researcher, diplomat. First-hand experience in research, operations and leadership in emergency responses to epidemics. 2005-12, Ethiopia’s Minister of Health; led a comprehensive reform of the country’s health system. 2012-16, Ethiopia’s Minister of Foreign Affairs; led efforts to negotiate the Addis Ababa Action Agenda, in which 193 countries committed to the financing necessary to achieve the Sustainable Development Goals. May 2017, elected Director-General, World Health Organization (WHO), for a five-year term by WHO Member States at the Seventieth World Health Assembly. First WHO Director-General to have been elected from multiple candidates by the World Health Assembly, and is the first person from the WHO African Region to serve as WHO's chief technical and administrative officer. Has outlined five key priorities for the organization: universal health coverage; health emergencies; women’s, children’s and adolescents’ health; health impacts of climate and environmental change; and a transformed WHO. Former: Chair, Roll Back Malaria Partnership Board; Co-Chair, Partnership for Maternal, Newborn and Child Health Board. Chair, Board, Global Fund to Fight AIDS, Tuberculosis and Malaria Board. Author of articles in scientific journals. Recipient of awards and honours.

Tedros Adhanom Ghebreyesus: “Prostituting himself”



World Health
Organization



The Global Fund (2009 to 2011)



The High Level
Taskforce on
Innovative
International
Financing for
Health Systems



IHME



Harvard School
of Public Health



Fig. Bill Gates and Tedros Adhanom Gherbreyesus

Director-General Tedros Adhanom Ghebreyesus is in the WHO to do Bill Gates' bidding



"If basics are not followed,
the only way this pandemic is
going to go: **it is going to get
worse and worse and
worse.**"

The Tigray People's Liberation Front (TPLF) and Dr Tedros Adhanom Ghebreyesus

Table: The United States has classified the TPFL as a Tier III terrorist organization.

199008020002	1990-08-02	Ethiopia	Kobo district	Tigray Peoples Liberation Front (TPLF)	17	0	Religious Figures/Institutions	Sub-Saharan Africa	Armed Assault	Firearms
198802180001	1988-02-18	Ethiopia	Unknown	Tigray Peoples Liberation Front (TPLF)	0	0	Private Citizens & Property,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Firearms
198410190003	1984-10-19	Ethiopia	Lalibela	Tigray Peoples Liberation Front (TPLF)	200	200	Private Citizens & Property	Sub-Saharan Africa	Hostage Taking (Barricade Incident)	Unknown
198308030001	1983-08-03	Ethiopia	Jari	Tigray Peoples Liberation Front (TPLF)	0	0	NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
198304200006	1983-04-20	Ethiopia	Korem	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	NGO,NGO,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
197905020020	1979-05-02	Ethiopia	Workamba	Tigray Peoples Liberation Front (TPLF)	100	0	Private Citizens & Property	Sub-Saharan Africa	Unknown	Unknown
197905020019	1979-05-02	Ethiopia	Aksum	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	Private Citizens & Property	Sub-Saharan Africa	Armed Assault	Unknown,Unknown



Dr Tedros Adhanom Ghebreyesus

* listed in the U.S. Homeland Security Global Terrorism Database

Positions Held:

Executive Member of the Tigray People's Liberation Front

Ethiopian Minister of Foreign Affairs

Ethiopian Minister of Federal Ministry of Health

<https://vaccineimpact.com/2020/is-w-h-o-director-tedros-a-terrorist-global-ties-to-bill-gates-clinton-foundation-dr-fauci-china-and-genocide/>

https://www.uscis.gov/sites/default/files/USCIS/Laws/TRIG/2014_Implementation_of_New_Discretionary_Exemption_for_Activities_or_Associations_Relating_to_TPLF.pdf



South African Government ✓



1h • 🌐

[#UbuntuAwards2022](#) | WHO Director-General @DrTedros Adhanom Ghebreyesus was surprised with the Special [#UbuntuHumanitarian](#) Award. Dr Ghebreyesus is currently in SA to discuss progress in making Africa self-sufficient in the production of [#COVID19](#) vaccines & related treatments.



WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"



Imperial College
London

Prof Neil Ferguson

Senior Research Fellow
Honorary Lecturer



World Health
Organization

JPMORGAN CHASE & CO.

Rockefeller
Brothers Fund
philanthropy for an Interdependent World

Google.org facebook. Eisai

STATE STREET

Pfizer The Pfizer Foundation

Baxter International Foundation

MSD
INVENTING FOR LIFE

COVID-19 Solidarity
Response Fund



Johnson & Johnson



GE Foundation



Dr Maria D. Van Kerkhove

COVID-19 Technical Lead of the World Health
Organization (WHO)

THE WORLD BANK
IBRD • IDA

Bloomberg
Philanthropies

INSTITUT
PASTEUR

Post-Doctoral Fellow

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



PhD Degree

W
wellcome



CONSIZE
CONSORTIUM FOR THE STANDARDIZATION
OF INFLUENZA SEROEPIDEMIOLOGY

DFID
Department for
International
Development

UKRI
Medical
Research
Council

CDC
CENTERS FOR DISEASE
CONTROL AND PREVENTION

unicef

NIH
Fogarty

NIH
National Institutes
of Health

BILL & MELINDA
GATES foundation



Undergraduate Degree

Stanford
MEDICINE
Masters Degree

WHO Dr Maria D. Van Kerkhove: “Globalist Hack and Elitist Puppet”

Imperial College
London



Home Publications

Dr Maria D Van Kerkhove

/// Faculty of Medicine, School of Public Health

Honorary Lecturer

■ Publications



FILTER

https://www.imperial.ac.uk/people/m.vankerkhove/publications.html?respub-action=search.html&id=00567652&limit=30&keywords=&iminyear=2002&imaxyear=2019&itypes=Book%2CBook+chapter%2CConference+paper%2CJournal+article%2COther%2CPatent%2CPoster%2CReport%2CScholarly+edition%2CSoftware%2CThesis+dissertation%2CWorking+paper&_type=on&type=Book&type=Book+chapter&type=Conference+paper&type=Journal+article&type=Other&type=Patent&type=Poster&type=Report&type=Scholarly+edition&type=Software&type=Thesis+dissertation&type=Working+paper&minyear=2002&maxyear=2019&page=1&person=true


WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"

virt BETA

Search 7500+ events

SUBMIT YOUR EVENT

[virt Top Picks](#) [This Week](#) [Past Events](#) [virt Africa](#) [virt India](#)



Dr Maria Van Kerkhove
TECHNICAL LEAD COVID-19
WHO Health Emergencies Programme

Centre for Mathematical Modelling of Infectious Diseases Annual Lecture 2021 with Dr Maria Van Kerkhove

London School of Hygiene and Tropical Medicine

Past Event

Global Health Security Agenda Architecture



Who We Are

The Panel for a Global Public Health Convention (GPHC) represents an independent coalition of global leaders working to strengthen the world's ability to prevent, prepare, and respond to infectious disease outbreaks before they become widespread pandemics.

The Panel was founded in 2020 in response to the emergence of the COVID-19 pandemic with the aim of bridging critical gaps in the **global public health architecture** and policy frameworks by promulgating a new **global public health treaty** or convention in an effort to ensure another pandemic of such magnitude does not happen again.


Capture of Global Health Security Agenda: WHO

No.		
1.	Authorize a Governing Body	Authorize one or more agencies to coordinate pandemic prevention, preparedness, and response globally—across regions, countries, and subnational jurisdictions
2.	Prepare and Respond	Give the global public health system—and its governing agency or agencies—the capability to flexibly and rapidly respond to a range of possible public health security threats and scenarios.
3.	Single Authoritative Source of Information	One agency must be designated to be the singular authoritative source for information , data, and technical assistance and to communicate a clear and compelling message to the world.
4.	Measure Progress	Build the capacity to objectively evaluate countries on their progress in achieving requirements and the capability to remediate identified deficiencies.
5.	Mechanisms to Enhance Compliance and Enforcement With International Agreements	Equip a pandemic prevention, preparedness and response governing body (or bodies) with appropriate enforcement mechanisms. These may include substantial incentives, disincentives for implementation for compliance and/or sanctions for noncompliance .
	Inspectorate function needed - ability to enter a territory for inspection and compliance verification.	Transparency of governments: <ul style="list-style-type: none"> - Immediate and transparent notification of outbreaks - Ongoing data sharing throughout - Acceptance of independent validation Independent monitoring of preparedness and response

Capture of Global Health Security Agenda: WHO

No.		
6.	Protect Governance Structure from Political Pressure	The governing body (or bodies) should be autonomous, with the freedom of self-governance and decision-making processes that are resistant to undue political pressures.
7.	Sustainable Funding	<p>Global pandemic prevention agencies must have sovereign control of sustainable financial resources and enduring, annual funding to:</p> <ul style="list-style-type: none"> • Lead globally all stages of infectious disease containment—especially prevention-related activities to prepare and respond to outbreaks before they become pandemics. • Build within-country public health core capacities. • Contingencies for possible emergencies in the future. <p>Financing: combination of compulsory and voluntary member state contributions; taxes on global private industry or international trade; and/or a permanent endowment from philanthropies, private companies and countries.</p>
8.	Ensure Representation and Accountability for All Nations	Ensure the governing framework represents all countries and other relevant nonstate stakeholders and is highly transparent and accountable.
9.	Involve all Parts of Society	At all levels of governance and action, involve multiple sectors, including national governments, the private sector, local governments and civil society.
10.	Ensure Responsibility	Ensure that individual countries understand the threat that infectious disease pandemics pose, take responsibility, are committed to these efforts and agree to fully comply and collaborate for the common good.

Global Health Security Agenda Architecture



Global Health Security Agenda



Private
Sector
Roundtable

Private Sector Roundtable on Global Health Security

Co-Chairs of Private Sector Roundtable (PSRT)



Dr Alan Tennenberg

Chief Medical Officer Global
Public Health, Johnson &
Johnson



Ashling Mulvaney

Vice President, Global Sustainability,
Access to Healthcare, AstraZeneca



Dr. David Barash

Chief Medical Officer and
Executive Director of Global
Health, GE Foundation





H.E. Dr Gro Harlem Brundtland

Co-Chair, GPMB; Former Prime Minister, Norway and Former Director-General, World Health Organization Bilderberger (1983)



Mr Elhadj As Sy

Co-Chair, GPMB, Secretary-General, International Federation of Red Cross and Red Crescent Societies Wellcome Trust



H.E. Dr Diane Gashumba

Minister of Health, Republic of Rwanda



H.E. Sigrid Kaag

Minister for Foreign Trade and Development Cooperation, The Netherlands



Dr Victor Dzau

President, The National Academy of Medicine, USA Director of PepsiCo (2005). Advisor NIH



Dr Chris Elias

President, Global Development Program, Bill & Melinda Gates Foundation, USA



Professor Ilona Kickbusch

Director, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland



H.E. Professor Veronika Skvortsova

Minister of Health, Russian Federation



Sir Jeremy Farrar

Director, Wellcome Trust, UK



Dr Anthony S. Fauci

Director, National Institute of Allergy and Infectious Diseases, USA



Dr Yasuhiro Suzuki

Chief Medical and Global Health Officer, Vice Minister for Health, Ministry of Health, Labour and Welfare, Japan



Dr Jeanette Vega Morales

Chief Medical Innovation and Technology Officer, La Red de Salud UC-Christus, Chile



Ms Henrietta Fore

Executive Director, UNICEF



Dr George F. Gao

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



Professor K. VijayRaghavan

Principal Scientific Advisor to the Government of India



Simulation Exercise

A simulation exercise (SimEx) can help develop, assess and test functional capabilities of emergency systems, procedures and mechanisms to be able to respond to outbreaks or public health emergencies.

The video will explain in 4 minutes the SimEx practice as promoted by WHO, including the definition, the different types of SimEx (table top exercise, drill, functional exercise and field/full scale exercise) and available resources.

“Simulation exercises have been identified as a key voluntary instrument in the validation of core capacities under the “Implementation of the International Health Regulations: Draft 5-year draft global strategic plan to improve public health preparedness and response”, which was adopted by the seventy first World Health Assembly. Simulation exercises, along with After Action Reviews, represent the functional assessment of capacities and complement States Parties annual reporting, independent reviews, and joint external evaluations. They play a key role in identifying the strengths and gaps in the development and implementation of IHR capacities and to support countries to assess the operational capability of their national capacity for public health preparedness and response.” – WHO

Simulation exercise calendar

Upcoming

- | | |
|----|--|
| SE | 15 September 2020 to 16 September 2020
Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020 |
| SE | 21 September 2020 to 25 September 2020
South Sudan-Uganda Regional cross border SimEx |
| SE | 21 September 2020 to 25 September 2020
South Sudan-Uganda Regional cross border SimEx |

Bill Gates, WEF, WHO and Covid-19 Simulations



Sponsored by John Hopkins University, World Economic Forum and Bill and Melinda Gates Foundation (BMGF) (October 2019)

Simulates an outbreak of a novel zoonotic coronavirus transmitted from bats to pigs to people that eventually becomes efficiently transmissible from person to person, leading to a severe pandemic. The pathogen and the disease it causes are modeled largely on SARS, but it is more transmissible in the community setting by people with mild symptoms. The pandemic is only stopped in its tracks with the timely vaccination of the entire global population

Gates Foundations Give Johns Hopkins \$20 Million Gift to School of Public Health for Population, Reproductive Health Institute

Dennis O Shea
Phone: 410.516.7160
Email: dro@jhu.edu

Lisbeth Pettengill
School of Public Health
Phone: 410.955.6878
Email: lpetteng@jhsph.edu

BALTIMORE -- The Bill & Melinda Gates Foundations have committed \$20 million to create the Bill & Melinda Gates Institute for Population and Reproductive Health at the Johns Hopkins University School of Public Health.

Bill & Melinda Gates Foundation
☎ 206-709-3400
✉ media@gatesfoundation.org
🐦 follow @gatesfoundation

BILL &
MELINDA
GATES
foundation

WORLD
ECONOMIC
FORUM

 **JOHNS HOPKINS**
BLOOMBERG SCHOOL
of PUBLIC HEALTH

Bill & Melinda Gates Institute for
Population and Reproductive Health

[Home](#)[Leadership](#)[Networks](#)[Resources](#)[News](#)[Calendar](#)[COVID-19](#)

Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020

Region:

European Region

Country:

Ukraine

Date of exercise:

15 September 2020 to 16 September 2020

To event remaining 4 days

Activity Type:

FX

Status:

Planned

Simulation exercise calendar

Upcoming

SE

15 September 2020 to 16 September 2020

[Ukraine -Regional EU Chem React 2 field exercise FX Sep.2020](#)

SE

21 September 2020 to 25 September 2020

[South Sudan-Uganda Regional cross border SimEx](#)

Intergovernmental Negotiating Body (INB)

Conflicts of Interest



**World Health
Organization**

Intergovernmental Negotiating Body



Ms Precious Matsoso

(South Africa)

- * Member of the Executive Board of World Health Organisation**
- * Director General of the National Department of Health, SA**

Co-Chairs of Intergovernmental Negotiating Body (INB)

(February 24, 2022)



Dr Roland Driece

(Netherlands)

- * Chair of the Global Health Security Agenda**
- * Vice-President, Conference of the Parties representing the European Region**

The INB was established to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response focused on a new revised International Health Regulations

International Health Regulations Committee (IHR)

Conflicts of Interest

International Health Regulations (IHR) Committee



Prof Arnold Monto,
University of Michigan

- * Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

- * Consultant for GSK, Novartis, Roche, Baxter and Sanofi
- * His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Neil M. Ferguson
Imperial College, London

- * Scientific Advisory Group for Emergencies (SAGE)
- * Head of International Health Regulations (IHR) (2005) Emergency Steering Committee

- * Consultant for Roche, Novartis, Baxter and GSK Biologicals
- * Funding from Sanofi, Janssen, Thermo-Fischer Scientific
- * Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

- * Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza
- * Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon
Deputy Director Public Health England


- * Member UK Scientific Advisory Group for Emergencies (SAGE)
- * Deputy Director Public Health England
- * Member of International Health Regulations (IHR) (2005) Steering Committee
- * Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London
- * UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.
- * Publications funding: Bill and Melinda Gates Foundation Wellcome Trust
- * Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization



Masato Tashiro

- * Director, WHO Collaborating Centre for Reference and Research on Influenza
- * WHO Essential Reference Laboratory of GISRS

Prof Neil Ferguson: Covid Modeller and Major Conflicts of Interest



**Benevolent
Philanthropist**



**Corporate
Hegemon**

OR

Wellcome Trust Ltd invested in Corporate Elite











Company	Investment Sector	Share Value (\$ millions)
Microsoft	IT, Software Development	\$942
Alphabet (Google)	Multinational Technology	\$801
Facebook (Metaverse)	Social Media Platform	\$509
Amazon	e-Commerce	\$592
Berkshire Hathaway	Asset Management	\$549
Bank Of America Corp	Corporate Banking Services	\$445
JP Morgan Chase & Co	Investment bank and Financial Services	\$391
Apple Inc	Computer electronics, software and online	\$747
Mastercard Inc	Multinational Financial Services	\$69
VISA INC	Multinational Financial Services	\$520
Door Dash Inc	Real Estate	\$744
Accenture	Information technology services and consulting	\$456
Cisco Systems	Cybersecurity, Cloud and Network	\$411
Adobe	Marketing and Document Management	\$357
Nike	Footwear, apparel, clothing, equipment	\$350
Krispy Kreme Inc	International doughnut and coffee chain	\$30
Pepsico	Transnational Beverage company	\$365
Royal Dutch Shell	Multinational Oil & Gas Corporation	\$301
BP	Multinational Oil & Gas Corporation	\$191

Wellcome Trust Ltd invested in Big Pharma

Company	Products	Share Value (\$ millions)
Johnson & Johnson	Pharmaceuticals, Covid Vaccines	\$407
Novartis	Covid Vaccines	\$371
Roche	Covid Pharmaceuticals, Vaccines	\$439
Abbott Laboratories	Drugs, Covid Diagnostic Kits (PCR)	\$246 (2 million shares)
Sequoia Pharmaceuticals	Vaccines	NA
Merck	Covid Pharmaceuticals, Vaccines	NA
Biogen	Neurotherapeutics	NA
Teva	Generic Covid Drugs	NA
Abbvie	Antivirals	NA
Syncona	Therapeutics	NA

NA – Not Available

Wellcome Trust invested in Covid-19 Industry

Shareholders	Covid Products	Value of Shares
	Ad26.COV2.S COVID-19 DNA Vaccine	£266m
	Regeneron RegN-Cov 2 Roche-Atea's Covid-19 pill ePlex SARS-CoV-2 Test Elecsys IL-6 test Elecsys Anti-SARS-CoV-2 antibody test cobas 5800 SARS-CoV-2 Qualitative Test	£326m
	 ensovibep dexamethasone	£275m
	BinaxNOW RAPID COVID ANTIGEN TEST Panbio™ COVID-19 Ag Rapid Test Device	£182m
	molnupiravir	NA
	VIR-7832 Covid-19 monoclonal antibody	NA
	NA	NA
	NA	NA
	NA	£273m

Wellcome Trust Ltd invested in Corporate Elite

thebmj

covid-19

Research ▾

Education ▾

News & Views ▾

Campaigns ▾

Jobs

Feature » Investigation

Covid-19, trust, and Wellcome: how charity's pharma investments overlap with its research efforts

BMJ 2021 ; 372 doi: <https://doi.org/10.1136/bmj.n556> (Published 03 March 2021)

The major funder of health research stands to gain financially from the pandemic, raising questions about transparency and accountability

The BMJ finds, **Wellcome itself holds investments in companies producing these same treatments**. Financial disclosures from late 2020 show that Wellcome has a £275m (€318m; \$389m) stake in Novartis, which manufactures dexamethasone and is investigating additional therapeutics. And Roche, in which Wellcome holds a £252m stake, is helping to manufacture monoclonal antibodies with Regeneron. Both Roche and Novartis report having had conversations with WHO's ACT Accelerator about their therapeutic drugs

Wellcome also influences the pandemic response through Farrar's position on the Scientific Advisory Group for Emergencies advising the UK government on covid-19, as well as his board seat on the Coalition for Epidemic Preparedness Innovations, a leading public-private partnership in the pandemic that has pledged more than \$1bn to covid-19 vaccine development

Wellcome reports gains of £3.3bn from all investments in 2020, three times more money than the trust gave away in charity

Two investment companies on the calls with Farrar—**Sequoia and Blackstone**—have paid out dividends to Wellcome in recent years

The Controllers of the World

≡ [Agenda](#) [Events](#) [Reports](#) [Platforms](#)



[Join us](#)



[Partners >](#)

[Home](#) [Articles](#) [Videos](#) [Live updates](#)

Blackstone Group

The Blackstone Group is an investment and advisory firm seeking to create positive economic impact and long-term value for its investors, the companies it invests in, the companies it advises and the broader global economy. Its alternative asset management businesses include the management of corporate private equity funds, real estate funds, hedge funds, funds of funds, debt funds, collateralized loan obligation vehicles, and closed-end mutual funds. It also provides financial advisory services, including M&A and restructuring and reorganization, and fund placement services.

Strategic Partner

Blackstone

Headquarters
USA

Wellcome Trust Ltd invested in Corporate Elite

Sequoia Pharmaceuticals Raises \$35 Million In Series C Financing

Published: Jan 09, 2007


GAITHERSBURG, Md., Jan. 8 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc. announced today that it has raised \$35 million in a Series C financing that will be used to further develop its pipeline candidates for the treatment of drug-resistant HIV infections, including the company's two lead clinical candidates, an HIV protease inhibitor as well as a novel therapeutic agent: a Pharmacokinetic Enhancer. The Wellcome Trust led the round of financing and was joined by other existing investors including Healthcare Venture, Sofinnova Partners, and Aberdare Ventures as well as new investor, MedImmune Ventures, Inc. As a result, Julie Eskay-Eagle of Wellcome Trust and Wayne T. Hockmeyer, Ph.D., President of MedImmune Ventures and Chairman of the Board, former CEO and founder of MedImmune, Inc., join the Sequoia board.

"We are delighted to have the continued endorsement of our current investors, led by Wellcome Trust, as well as to have a new investor in MedImmune Ventures in this round of financing," said Cindy Collins, President & CEO, Sequoia Pharmaceuticals.



Wellcome Trust invested in Covid-19 Industry

BERKSHIRE
HATHAWAY INC.



Wellcome Trust invested in Covid-19 Industry

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST ownership in BRK.A / Berkshire Hathaway, Inc.

Security BRK.A / Berkshire Hathaway, Inc.

Institution WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST

Latest Disclosed Ownership 1,038 shares

Latest Disclosed Value \$ 549,020,000

Fintel®

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST ownership in BRK.A / Berkshire Hathaway, Inc.

2022-04-27 - WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST has filed a 13F-HR form disclosing ownership of 1,038 shares of Berkshire Hathaway, Inc. (US:BRK.A) with total holdings valued at \$549,020,000 USD as of 2022-03-31. WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST had filed a previous 13F-HR on 2022-02-01 disclosing 1,038 shares of Berkshire Hathaway, Inc. at a value of \$467,787,000 USD. This represents a change in shares of 0.00 percent and a change in value of 17.37 percent during the quarter.

Berkshire Share Holdings	Total Investment Value
Merck & Co.	\$ 1,415,927,482
Bristol-Myers Squibb Co.	\$ 2,080,710,820
Pfizer Inc	\$136 million
Johnson & Johnson (JNJ)	\$ 55,921,016
Teva Pharmaceutical Industries Ltd	\$ 471,538,031
Mastercard Inc (MA	\$ 1,678,004,306
Vanguard 500 Index Fund ETF	\$ 16,403,210
Bank of America Corp	\$ 43,792,925,054



BERKSHIRE
HATHAWAY

Fig. Warren Buffet, CEO Berkshire Hathaway Inc.

Wellcome Trust invested in Covid-19 Industry



11 Jan 2022

Wellcome Trust to spend £16bn on research with focus on Covid vaccines

Britain's biggest charity unveils spending plan over next decade after record return on investments

Wellcome Trust: Global Elite Co-Conspirator in Covid-19 Pandemic Genocide and Conflicts on Interest

Wellcome Trust - Imperial College Centre for Global Health Research

FOLLOW

+ PROJECT

+ POST

+ EVENT



Michael Levin



0 Collaborator(s)



Funding source

Wellcome Trust (WT)

Info

People

Posts

Our vision is to contribute to understanding, preventing, and treating the major health problems of low- and middle-income countries (LMICs), through partnerships with academic institutions in Africa, Asia, and Latin America. We will integrate Imperial College London (ICL)'s expertise in Science, Engineering, Medicine, Public Health and Policy to study the health problems of global importance and build local research excellence. Collaborating teams will be supported to address major health problems of partner LMIC countries. Our Focus will be: 1. Mechanisms and population dynamics of tuberculosis (TB), HIV, HIV-TB, malaria, and neglected tropical diseases (NTDs). 2. Vaccine prevention and treatment of major childhood infections. 3. Non-communicable diseases (NCD's) including trends, risks and management of cardiometabolic conditions, chronic respiratory diseases, and selected cancers. 4. Integration of infection-NCD mechanisms and prevention including the role of infections and parasitic diseases on cancers and cardiovascular diseases; smoking and diabetes on TB susceptibility and progression; and the NCD

START DATE

2013-10-07

END DATE

2018-10-06

CANCER TYPES

Melanoma of skin

All cancers but non-melanoma skin cancer

PROJECT TYPES

Cancer Treatment

Cancer Prevention

Wellcome Trust Ltd invested in Corporate Elite



Williams Burns

CEO of Roche Holdings, is one of the Board of Governors of Wellcome Trust



Elhadj As Sy

Co-chair of the WHO/World Bank Global Pandemic Preparedness Monitoring Board, and Board of Governors of Wellcome Trust



Wellcome Trust invested in Covid-19 Industry

Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19



SEATTLE, March 10, 2020 – The Bill & Melinda Gates Foundation, WELLCOME, and Mastercard today committed up to \$125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.



BILL &
MELINDA
GATES
foundation



Mastercard

Wellcome Trust Investment Portfolio 2020

We manage a significant portion directly...



Our direct shareholdings are a diverse subset of the world's best companies. We hold these stocks with a long term view, leading to very low turnover.

Wellcome Trust Investment Portfolio 2021

Wellcome Bond Investor Update Presentation (11th January 2022)



Wellcome Trust invested in Covid-19 Industry

Wellcome Trust has been at the Centre of the Global Pandemic Response

We are dedicated to improving health and we fund health-related research across the world

Wellcome has played a key role in the global pandemic research response

We are active participants in CEPI, (which Wellcome helped to found), Gavi and the WHO.

Some examples of Wellcome's role in the global pandemic response:



The Covid-19 Therapeutics Accelerator (CTA) started in March 2020 with support from Wellcome, Mastercard and the Bill & Melinda Gates Foundation. In its first year, the CTA committed over \$90m to clinical trials, therapeutic candidate discovery research, platforms to collect real-world evidence and data, and extra manufacturing capacity



Wellcome is part of the **Access to Covid-19 Tools (ACT) Accelerator**, which was set up by the WHO to ensure **global equitable access to the best vaccines and treatments**



The **RECOVERY trial**, which Wellcome supports through core funding and grants, has been at the **forefront of testing potential treatments** and identifying those that are effective at reducing the severity of illness people experience.




The Wellcome Sanger Institute is providing **large-scale, high-throughput genome sequencing and analysis of the Covid virus**, alongside many other avenues of research to support the pandemic response in the UK and internationally. This has not stopped other programmes of research from continuing, including work on human and animal genetics.

Wellcome Trust invested in Covid-19 Industry


A Globally Diversified Portfolio...

By Asset Class



- The portfolio is diversified both across and within asset classes
- The portfolio's exposure to public equities as a proportion to total assets reduced through FY 2020/21 due to the strong performance of our private investments.
- Our exposure to private equity increased due to exceptional performance. The largest part of our private equity exposure is venture capital, which continues to benefit from rapid technological innovation and a structural shift to the digital economy.

By Sector (of Public and Private Equity Exposure)



- There has been little change to our public and private equity sector positioning over FY 2020/21. Exposure to information technology sector increased slightly from 25% to 28%, while consumer discretionary (which includes e-commerce) exposure remains at 19%.
- While healthcare and consumer staples have performed relatively poorly, there are some pockets of value which we have added to. We have increased our healthcare exposure slightly to 13%.

Wellcome Trust invested in Vaccine Industry



FINANCIAL TIMES

Subscribe Sign In

HOME WORLD US COMPANIES TECH MARKETS CLIMATE OPINION WORK & CAREERS LIFE & ARTS HOW TO SPEND IT

Become an FT subscriber to read:

Merck and Wellcome Trust in vaccine alliance

Make informed decisions with the FT

Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.



Wellcome Trust invested in Vaccine Industry



Filling the need for trusted information on national health issues

DONATE



TRENDING

COVID-19 Vaccine Monitor Dashboard

Mental Health

Public Health Emergency

Home // Global Health Policy // KFF Daily Global Health Policy Report // January 25, 2011

Merck, Wellcome Trust Back Project To Develop Improved Rotavirus Vaccine For Developing Countries

Jan 25, 2011



"A joint venture between U.S. drugmaker Merck and Britain's Wellcome Trust charity said on Monday it is working on an oral rotavirus vaccine designed to be cheaper and easier to use than current shots," [Reuters](#) reports. "Hilleman Laboratories, an India-based joint venture set up on a not-for-profit basis in 2009, said the vaccine will aim to protect against diarrhea-causing rotavirus infections and will be based on thin strips or granules that dissolve in the mouth and can be easily transported, stored and administered."

SEARCH NEWS SUMMARIES FOR:

Enter Keyword



RECENT REPORTS

- › December 17, 2020
- › December 16, 2020
- › December 15, 2020
- › December 14, 2020
- › December 11, 2020

Wellcome Trust invested in Vaccine Industry



<https://www.merck.com/leadership/julie-l-gerberding-m-d-m-p-h/>



Julie Louise Gerberding, M.D., M.P.H.

**Executive Vice-President and Chief Patient Officer,
Strategic Communications, Global Public Policy and
Population Health, MSD**

Previous Positions

President of Vaccines, Merck (2010)

Director of the U.S. CDC (through SARS)

MSD Wellcome Trust Hilleman Laboratories, Board Member)



Wellcome Trust invested in Vaccine Industry



Wellcome Trust to launch £200 million investment business for healthcare and life sciences

The Board of Governors of the Wellcome Trust has approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors.

Wellcome Trust invested in Vaccine Industry

March 8, 2019 10:33 AM EST | Discovery


[G](#) [in](#) [T](#)

ENDPOINTSNEWS

Merck gives King's College London, Wellcome Trust up to \$340M in deal to develop non-opioid painkillers



Natalie Grover
Reporter



MERCK

KING'S
College
LONDON

W
wellcome

Wellcome Trust invested in Vaccine Industry

THE ECONOMIC TIMES | Industry

English Edition | E-Paper

Subscribe

Sign In

Get Benefits Worth Rs. 3700



Home



ETPrime

Markets

News

Industry

RISE

Politics

Wealth

Mutual Funds

Tech

Jobs

Opinion

NRI

Panache

ET NOW

More



Auto ▾ Banking/Finance ▾ Cons. Products ▾ Energy ▾ Renewables ▾ Ind'l Goods/Svs ▾ Healthcare/Biotech ▾ Services ▾ Media/Entertainment ▾ More ▾

Business News › Industry › Healthcare/Biotech › Healthcare › Wellcome, Merck JV to make anti-diarrhoea vaccine for babies

Wellcome, Merck JV to make anti-diarrhoea vaccine for babies

ET Bureau • Last Updated: Jan 25, 2011, 06:41 AM IST



SHARE



FONT SIZE



SAVE



PRINT



COMMENT

Synopsis

An Indian healthcare JV between Merck & Co and Wellcome Trust plans to develop heat stable oral rotavirus vaccine to prevent diarrhoea in babies in developing countries.

NEW DELHI: An Indian healthcare joint venture between drugmaker Merck & Co and UK-based charitable entity [Wellcome Trust](#) plans to develop heat stable oral rotavirus vaccine to prevent diarrhoea in babies in developing

Wellcome Trust secret offshore investments

[NEWS](#)[CAREERS](#)[COMMENTARY](#)[JOURNALS](#)

Science

[LOG IN](#)[BECOME A MEMBER](#)[News Home](#)[All News](#)[ScienceInsider](#)[News Features](#)[GET OUR E-ALERTS](#)

[HOME](#) > [NEWS](#) > [SCIENCEINSIDER](#) > [PRIVATE RESEARCH FUNDERS COURT CONTROVERSY WITH BILLIONS IN SECRETIVE INVESTMENTS](#)

[SCIENCEINSIDER](#) | [FUNDING](#)

Private research funders court controversy with billions in secretive investments

Critics say offshore investing by high-minded foundations shores up a nefarious system


6 DEC 2018 • BY [CHARLES PILLER](#)

Wellcome Trust secret offshore investments

European Scientist



 Join our newsletter EN

Energy | Environment | Agriculture | Big Data | Public Health | Research | Features |  Search...

[Home](#) » [Environment](#) » [Major research funders are stowing billions in offshore tax havens](#)

- Environment -

Major research funders are stowing billions in offshore tax havens



By Siobhán Dunphy - 06.12.2018



Wellcome Trust is invested in 57 offshore tax haven funds

Wellcome Trust secret offshore investments

TheScientist
EXPLORING LIFE, INSPIRING INNOVATION




Home / News & Opinion

Research Funders Make Secretive Overseas Investments: Report

An investigation by *Science* reveals that charities' investments support activities opposed to their own missions, such as human health and environmental protection.

Ashley P. Taylor

Dec 6, 2018

 PDF VERSION

Many big-name research funders place millions of dollars in offshore investments, which in turn may drive activities that run contrary to the causes the charities promote, according to an investigative report published today (December 6) in *Science*.

ABOVE: The Cayman Islands sometimes serve as a tax haven.
© ISTOCK.COM, [UNDEFINED](#)

The investigation covered the investments of seven of the world's largest science funders. Of those, six charities—the Wellcome Trust, the Howard Hughes Medical Institute, the Robert Wood Johnson Foundation, the David and Lucile Packard Foundation, the Gordon and Betty Moore Foundation, and the William and Flora Hewlett Foundation—were found to have offshore investments that, combined, totaled at least \$5 billion in recent years. The one charity that was not found to invest offshore is the Bill &

Wellcome Trust secret offshore investments

[NEWS](#)[CAREERS](#)[COMMENTARY](#)[JOURNALS](#) ▾

Science

Foundation	Endowment assets*	Known offshore investments
Bill & Melinda Gates Foundation	\$51.8 billion	None
Wellcome Trust	\$29.3 billion	\$926 million
Howard Hughes Medical Institute	\$20.4 billion	\$891 million
Robert Wood Johnson Foundation	\$10.8 billion	\$3+ billion
William and Flora Hewlett Foundation	\$9.9 billion	\$168 million
David and Lucille Packard Foundation	\$7.9 billion	\$140 million
Gordon and Betty Moore Foundation	\$6.9 billion	\$40 million

PARADISE PAPERS; FOUNDATIONS' MOST RECENT TAX RETURNS AND AUDITED FINANCIAL STATEMENTS

**Foundations that invest in tax havens need to know
that ... they are alongside criminals, tax evaders, and
kleptocrats.**



Epidemiological modelling to support the global COVID-19 response:
how to mitigate impact in low-income and crisis-affected settings

Dr Patrick Walker

Imperial College London, United Kingdom

Prof Azra Ghani

Imperial College London, United Kingdom

Prof Nicholas Grassly

Imperial College London, United Kingdom

Prof Neil Ferguson

Imperial College London, United Kingdom

Scientific Advisory Group for Emergencies (SAGE), UK: Major Conflicts of Interest



Joint Committee on Vaccination and Immunisation (JVCI), UK and Conflicts of Interest

Advises UK Health Departments on Vaccination

Committee Member	Disclosed and Undisclosed Interests	Funding and Grants
<p>Prof Lim Wei Shen (Chair, Nottingham University Hospitals)</p> <p>Appointed Chair of the JCVI sub-committee on COVID-19 vaccines (Prof Andrew Pollard recused himself – perceived conflict of interest)</p>	<ol style="list-style-type: none"> Chief Investigator in research study funded by Co-investigator of the NIHR-funded (COVID19) RECOVERY Trial Expert Panel Member: NICE COVID19 Guidelines Member of UK Specialist Commissioning Group – Remdesivir, Tocilizumab Nottingham University 	<p>Pfizer. £25,001 (2021)</p> <p>National Institute for Health Research, UK MRC Wellcome Trust, Gates Foundation. AbbVie, Regeneron, Roche</p> <p>\$13,510,155 (Gates Foundation)</p>
<p>Prof Anthony Harnden</p> <p>Deputy Chair (University of Oxford)</p>	<ol style="list-style-type: none"> Partner at an Oxfordshire Practice which is a PCN lead practice for COVID- 19 vaccine administration. Member of the Covid-19 Vaccine Deployment Clinical Review Group University of Oxford 	<p>\$278,724,831 (Gates Foundation)</p>
<p>Dr Kevin Brown</p>	<ol style="list-style-type: none"> Public Health England Co-authored favourable study on the “real world effectiveness” of the Pfizer & AZ jabs 	<p>\$7,451,295 (Gates Foundation)</p>
<p>Professor Adam Finn</p> <p>(University of Bristol)</p>	<ol style="list-style-type: none"> Chief investigator in the Valneva COVID19 vaccine clinical trials programme in the UK and in the Sanofi COVID19 booster vaccine clinical trial in the UK Principal or Co-investigator in the Oxford-Astra Zeneca COV001, COV002 and COV006 studies and the National Immunisation Schedule Evaluation Consortium study ComFluCov. Detecting SARS-CoV-2 variants Study grant from GlaxoSmithKline (GSK) Head of Pfizer Vaccine Centre of Excellence at the University of Bristol Chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) 	<p>Pfizer, Sanofi-Aventis, Gates Foundation</p> <p>AstraZeneca. Janssen</p> <p>Wellcome Trust</p> <p>£4.6 million (Pfizer)</p>

Joint Committee on Vaccination and Immunisation (JCVI), UK and Conflicts of Interest

Advises UK Health Departments on Vaccination

Committee Member	Disclosed and Undisclosed Interests	Funding and Grants
Professor Andrew Pollard (Chair JCVI)	<ol style="list-style-type: none"> 1. Recused himself from all JCVI COVID-19 meetings 2. Chief Investigator - Oxford-Jenner AstraZeneca Sars-coV-2 Vaccine Trial 3. WHO's Strategic Advisory Group of Experts board member 4. Chair - National Institute for Health and Care Excellence (NICE) 5. Director of the Oxford Vaccine Group 	Partnership AstraZeneca
Professor Maarten Postma (University of Groningen)	<ol style="list-style-type: none"> 1. Infect Dis Ther. 2018 Sep;7(3):353-371. Contributing author 2. Infect Dis Ther. 2019 Mar; 8(1): 1–3.. Contributing author 3. Expert Review of Vaccines, Volume 11, 2012 - Issue 10 4. Lancet. 2021 Aug 7; 398(10299): 503–521 5. Received grants, honoraria from all companies developing, producing, and marketing non-vitamin K oral anticoagulants (NOACs) 6. Independently received Grants, Honouria, personal fees 7. Shareholder in pharmacology company 8. Adviser to the consultancy company 	<p>Funded by Pfizer. Received grants and honouria from Pfizer Pfizer paid consultant Funded by Pfizer Bill & Melinda Gates Foundation Boehringer Ingelheim, Pfizer, Bayer, Daiichi-Sankyo and Bristol-Myers Squibb GSK, Astra Zeneca, Biomarin, MSD, Merck, Sanofi, Novartis, Novavax, BMS, IQVIA, Seqirus; Quintiles, Novartis, Pharmerit, Bayer, DIKTI, LPDP, Budi, WHO, Antilope, FIND, EU, and BioMerieux Holds stocks Ingress Health and Pharmacoeconomics Advice Groningen (PAG Ltd), Health-Ecore Asc Academics</p>
Professor Anthony Scott (Director of the Health Protection Research Unit - London School of Hygiene & Tropical Medicine)	<ol style="list-style-type: none"> 1. Wellcome Trust Senior Research Fellow in Clinical Science 2. He receives research funding from the National Institute for Health Research, the Medical Research Council, the Wellcome Trust and Gavi, The Vaccine Alliance, and the Bill & Melinda Gates Foundation. 3. London School of Hygiene & Tropical Medicine (employer) 	\$308,640,471

Covid Vaccines: Major Conflicts of Interests



Developers of Oxford-AstraZeneca
Vaccine Tied to UK Eugenics Movement

A woman with blonde hair, wearing a white lab coat, is looking through the eyepiece of a microscope in a laboratory. The background is slightly blurred, showing laboratory equipment and a wooden wall. The text 'wellcome trust' is overlaid in white, bold, lowercase letters across the center of the image.

wellcome trust

Part of Eugenics history

Depopulation

In Africa

Galton
Institute

formerly

“The Eugenics
Society”



Professor Adrian Hill

Director of the Jenner Institute at Oxford

Lead developer of the Oxford-AstraZeneca vaccine

UK advisor on Vaccine roll out


Spoke at Galton Institute 100-year Heritage Event

Covid Vaccines: AstraZeneca/Oxford/Welcome Trust and Eugenics Movement



BILL & MELINDA
GATES *foundation*

The Engender Health Society, earlier known as, The Sterilization League for Human Betterment has its origins in the Eugenics movement, The Birth Control Movement with its emphasis on Population control. More recently, they have veiled their programs under the guise of family planning and female reproductive rights. They have teamed up with partners the Galton Institute and the Gates Foundation to spread their benevolence in Africa and South East Asia.





Professor Adrian Hill
Wellcome Trust Senior Investigator
Lead developer of the
Oxford-AstraZeneca vaccine

wellcometrust
Wellcome Trust's Centre for Human Genetics

Our Team



Professor Adrian Hill

Professor Adrian Hill is the Director of the Jenner Institute at Oxford University and a Wellcome Trust Senior Investigator, Professor of Human Genetics and a NIHR Senior Investigator.

Read more.



He heads a leading malaria vaccine development programme and also regularly consults nationally on pandemic threats. His group led the first clinical vaccine trial against the Ebola virus outbreak strain in the major West African emergency in 2014. Professor Hill's immunogenetics programme focuses on genome-wide and exome-wide association studies of bacterial diseases, particularly tuberculosis and pneumococcal disease, in African and European populations.



BRAAVOS (9%)

Deutsche Bank

Google

ventures



vaccitech

wellcome trust



HM Government

£5 million



THE JENNER
INSTITUTE

DEVELOPING INNOVATIVE VACCINES



GlaxoSmithKline



HM Government

South Africa's Covid-19 Vaccine Trial

TRW

LATEST HARD FORK PLUGGED README GROWTH QUARTERS NEURAL

Bill Gates commits \$750M to help Oxford vaccinate the world against COVID-19

In 2020, **The Bill and Melinda Gates Foundation** (via the **Coalition for Epidemic Preparedness Innovations (CEPI)**; and the **Gavi Vaccine Alliance (Gavi)** teamed up with British-Swedish pharmaceutical firm **AstraZeneca**, who had joined forces with Oxford University's, Jenner institute through its **Vaccitech**, spin-off company in collaboration with **Advent Srl** (part of the Italian-based, IRBM Group) on the development and pharmaceutical giant, **Merck Group** on the manufacture Two billion doses of **AZD1222**, in other words, **COVID-19 vaccine**.

BILL & MELINDA
GATES foundation



vaccitech



MERCK





UNIVERSITY OF
OXFORD

THE  **Pirbright**
INSTITUTE

Studies at Pirbright demonstrate two doses of Oxford University's COVID-19 vaccine boosts immune response in pigs

Posted: 23 June, 2020


The Pirbright Institute, working in collaboration with the [University of Oxford](#) [↗](#) have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs.

Latest Releases

[Pirbright's new bird flu vaccine provides rapid protection, could reduce virus spread and is less costly to produce](#)

[Pirbright scientists will progress pig and cattle health through two projects worth €3.5 million](#)

[Landmark study by Pirbright uncovers crucial details of lumpy skin disease virus transmission](#)



National Institute
of Allergy and
Infectious Diseases

**AstraZeneca receives \$1 billion in U.S.
funding for Oxford University
coronavirus vaccine**

PUBLISHED THU, MAY 21 2020-6:09 AM EDT | UPDATED THU, MAY 21 2020-10:33 AM EDT



SOUTH AFRICA INC.



World Health
Organization

“LAPDOG”

Prof Salim Abdool Karim: A 'Global Élite' Puppet

BILL & MELINDA GATES foundation
Scientific Advisor

CAPRISA
CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA
Director and co-Founder

saMRC
advancing life
Former President and CEO

COLUMBIA
MAILMAN SCHOOL OF PUBLIC HEALTH
HARVARD UNIVERSITY
CORNELL UNIVERSITY
FOUNDED A.D. 1865
Adjunct Professor

THE ROYAL SOCIETY
Fellow of the Royal Society (FRS)

MRC HIV-TB Pathogenesis and Treatment Director


MIT
Massachusetts Institute of Technology
Associate

PEPFAR
U.S. President's Emergency Plan for AIDS Relief
Advisor

mBio
Editorial Board

iavi
International AIDS Vaccine Initiative
Scientific Advisory Committee

The Global Fund
To Fight AIDS, Tuberculosis and Malaria
Professor of Global Health



Prof Salim Abdool Karim

South African Ministerial Advisory Committee on COVID-19 Over-Archiving Chair
Republic of South Africa

MERCK
Consultant

UNAIDS
Chair: UNAIDS Scientific Expert Panel

NIH
NIAID
USAID
FROM THE AMERICAN PEOPLE
EU
Funders

World Health Organization
WHO Science Council HIV and Hepatitis Scientific and Technical Advisory Group
WHO HIV-TB Task Force Chair of the Scientific and Technical Advisory Group for Reproductive Health

UNIVERSITY OF KWAZULU-NATAL
INYUVESI YAKWAZULU-NATALI
Pro-Vice-Chancellor

The NEW ENGLAND JOURNAL of MEDICINE
Editorial Board

POPULATION COUNCIL
Ideas. Evidence. Impact.
Board Member

THE LANCET Global Health
THE LANCET HIV
Editorial Board

THE LANCET COVID-19 COMMISSION
Commissioner

The ROCKEFELLER FOUNDATION
Scholarship, 1987

LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE
Masters Scholarship, 1987

CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION
Studied, 1988



CAPRISA

CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

WORLD
ECONOMIC
FORUM

Karim's ties to the Global Elite: CAPRISA in cohorts with World Economic Forum



Generating Knowledge - Impacting Health

[HOME](#) [ABOUT US](#) [RESEARCH](#) [SCIENTIFIC PUBLICATIONS](#) [MEDIA](#) [NEWSLETTERS](#) [CAREERS](#) [FELLOWSHIP PROGRAMME](#) [CONTACT](#)

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS

CAPRISA participates at the World Economic Forum for Africa

2 June 2017

CAPRISA Director Professor Salim and Associate Scientific Director Quarraisha Abdool Karim participated in sessions at the World Economic Forum(WEF) for Africa held from 3-5 May in Durban. Prof Salim Abdool Karim participated in the Leadership Council of the Coalition for African Research and Innovation (CARI) together with Dr Francis Collins Director of the National Institutes of Health and Dr Nicola Mulder from the University of Cape Town. This session focussed on strategic business models, governance, financial options and African-led networks to develop innovative research platforms and sustain research in Africa.

Professor Quarraisha Abdool Karim was a speaker in the session on Laying the Groundwork for Research and Innovation, which examined how government and business leaders foster viable pan-African research and innovation ecosystems. The panel, which included representatives from the African Academy of Sciences and the Bill and Melinda Gates Foundation, among others, explored scenarios on expanding funding mechanisms, building local capacity for R&D and prioritising intra-African science partnerships.

To listen to this session [click here](#)

Archives

Latest Posts

[2021](#)
[2020](#)
[2019](#)
[2018](#)
[2017](#)
[2016](#)
[2015](#)
[2014](#)
[2013](#)



CAPRISA participates at the World Economic Forum



Fig: Prof Salim Abdool Karim (left) participated in the Leadership Council of the Coalition for African Research and Innovation (CARI) together with Dr Francis Collins Director of the National Institutes of Health (middle) and Dr Nicola Mulder (right) from the University of Cape Town. World Economic Forum(WEF) for Africa held from 3-5 May 2017, in Durban



**participates at
the World
Economic
Forum (May 2017)**

**Quarraisha Abdool Karim,
Associate Scientific Director**



Karim's ties to the Global Elite



Generating Knowledge - Impacting Health

HOME ABOUT RESEARCH SCIENTIFIC PUBLICATIONS MEDIA NEWSLETTERS CAREERS FELLOWSHIP PROGRAMME ALUMNI CONTACT

Home / Media / News and Events

LATEST NEWS AND EVENTS

Quarraisha Abdool Karim named as UNAIDS Special Ambassador for Adolescents & HIV

13 December 2017

CAPRISA's Associate Scientific Director, Professor Quarraisha Abdool Karim, has been appointed as a UNAIDS Special Ambassador. In this new role, she will focus on adolescents and HIV, while also championing the involvement of young women in science.

"I am delighted that Quarraisha Abdool Karim has accepted this position," said Mr Michel Sidibé, Executive Director UNAIDS.

Sidibé made the announcement at the launch of the UNAIDS report, Right to Health, on Monday 20 November, at the Michael Mapongwana Community Health Centre, Harare, Khayelitsha, in Cape Town. There was a strong community presence at the event, which was attended by the Minister of Health, Dr Aaron Motsoaledi, representatives of TAC and several civil society organisations.

Sidibé said that Abdool Karim was "a strong and consistent champion of young people living with and affected by HIV." He said that she will use her new honorary position as Special Ambassador "to continue to translate scientific research and knowledge into people-centred solutions and prevention programmes to reduce the factors making young people so vulnerable to HIV infection. UNAIDS looks forward to supporting her work."

Responding to her appointment Abdool Karim said that "as we increase our understanding of the HIV epidemic and the transmission dynamics that place young people at higher risk of infection, all sectors of society must work together to make sure that adolescents have access to the information and services that can keep them safe and well through a crucial period of their lives and into adulthood."

Abdool Karim has made pioneering contributions to understanding the HIV epidemic in young people, especially in young women.



Fig: Michel Sidibé (left), Executive Director UNAIDS, presents a certificate of appointment as a UNAIDS Special Ambassador for Adolescents and HIV to Professor Quarraisha Abdool Karim (middle). On her left is the South African Minister of Health, Dr Aaron Motsoaledi

**What about the
Depopulation Program?**

Karim, The Population Council and the Depopulation Program

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS



Salim Abdool Karim appointed to Population Council Board of Trustees

13 December 2017

The Population Council announced the appointment of CAPRISA's Director and leading AIDS researcher Professor Salim Abdool Karim, to the Council Board of Trustees. Abdool Karim joins 15 other Board members at the Population Council, drawing from six different countries and diverse areas of expertise, including demography, economics, education, HIV and AIDS, international law, obstetrics and gynaecology, public health and reproductive health. The Population Council's research in biomedical, social science and public health in 50 countries, aims to develop solutions that will contribute to more effective policies, programs, and technologies that improve lives around the world. The Council, a non-profit, nongovernmental organisation, which addresses critical health issues is based in New York.

**POPULATION
COUNCIL**

Ideas. Evidence. Impact.



Prof Salim Abdool Karim,
CAPRISA Director

Karim, The Population Council and the Depopulation Program




Fig. JD Rockefeller




Fig. William H. Gates Sr.



Fig. Prof Salim
Abdool Karim

KENYA CONFERENCE OF CATHOLIC BISHOPS
CATHOLIC HEALTH COMMISSION OF KENYA

KENYA CATHOLIC SECRETARIAT
Waumini House, Westlands
P.O. Box 13475 - 00800, Nairobi
Tel: +254 020 4443133/4/5, / 4443906,4443917
Fax: +254 020 4442910,4441758
Email: health@catholicchurch.or.ke /
secgeneral@catholicchurch.or.ke
Website: www.kccb.or.ke

Our Ref:
Your Ref:

To all Kenyans and people of good will,

**RE: The Final Scientific Report of the Tetanus Vaccine Used in Mass
Vaccination Campaigns in March and October 2014**

**BILL & MELINDA
GATES foundation**

Novarel®
(Chorionic Gonadotropin for Injection, USP)
Rx only
FOR INTRAMUSCULAR USE ONLY
10,000 USP units
1 vial of Chorionic Gonadotropin for Injection, USP
1 vial of Bacteriostatic Water for Injection, USP, 10 mL

Novarel®
(Chorionic Gonadotropin for Injection, USP)
Rx only
FOR INTRAMUSCULAR USE ONLY
5,000 USP units
1 vial of Chorionic Gonadotropin for Injection, USP
1 vial of Bacteriostatic Water for Injection, USP, 10 mL

“This proved right our worst fears; that this WHO campaign is not about eradicating neonatal tetanus but a well-coordinated forceful population control mass sterilization exercise using a proven fertility regulating vaccine.”



Dr. Ngare
Kenya Catholic Doctors Association



Karim's ties to the Global Elite



<https://www.caprisa.org/NewsAndEvents/Read/10416>

Generating Knowledge - Impacting Health

HOME ABOUT RESEARCH SCIENTIFIC PUBLICATIONS MEDIA NEWSLETTERS CAREERS FELLOWSHIP PROGRAMME ALUMNI CONTACT

Home / Media / News and Events

LATEST NEWS AND EVENTS

Coalition for African Research and Innovation



Quarraisha Abdool Karim invited to serve on CARI

30 August 2019

Professor Quarraisha Abdool Karim, Associate Scientific Director at CAPRISA has been invited to serve as an advisor on the Coalition for African Research and Innovation (CARI) that focuses on advancing scientific capacity in the development of sub-Saharan Africa.

Dr Felix Dapare Dakora, President of the African Academy of Sciences and Dr Francis Collins, Director National Institutes of Health said they were "especially interested in discussing measures and incentives to create sustained public and private investment in African research institutions and to achieve the Sustainable Development Goals' health targets by 2030."

"Scientific innovation in Africa is on the rise, and momentum is building for new measures to strengthen and sustain the capacity of African universities and research institutions to become an effective force for economic growth and local solutions for health and development challenges."

Abdool Karim said it was a privilege to contribute and advance CARI's vision in this important initiative on the African continent.

CARI is the strategic partnership of the African Academy of Sciences, African Union Development Agency, U.S. National Institutes of Health, Wellcome Trust, and the Bill & Melinda Gates Foundation to explore opportunities and galvanise support to create a strengthened, sustainable, and autonomous African biomedical research enterprise.


Latest Posts

2022
2021
2020
2019
2018
2017
2016
2015
2014
2013

Partners and
Funders



BILL & MELINDA
GATES foundation



Karim's ties to the Global Elite



Generating Knowledge - Impacting Health

HOME ABOUT RESEARCH SCIENTIFIC PUBLICATIONS MEDIA NEWSLETTERS CAREERS FELLOWSHIP PROGRAMME ALUMNI CONTACT

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS


CAPRISA Director appointed Adjunct Professor of Immunology and Infectious Diseases at Harvard 30 August 2019

We congratulate Professor Salim Abdool Karim, Director of CAPRISA, on his appointment as an Adjunct Professor in Immunology and Infectious Diseases at Harvard University. As an adjunct honorary appointment, his responsibilities at Harvard are mainly related to research and occasional teaching.

Abdool Karim conveyed his deep gratitude to Quarraisha Abdool Karim, his family, the Board of Control and Scientific Advisory Board members, the excellent CAPRISA research team and his friends and colleagues, saying that "this achievement would not have been possible without their strong support and encouragement." This appointment is a major accolade for CAPRISA and Abdool Karim's accomplishments as its Director. "It reflects the excellence achieved in research at CAPRISA," he said



HARVARD
MEDICAL SCHOOL



**Prof Salim Abdool Karim, CAPRISA
Director**

Karim's CAPRISA ties to the Global Elite



Generating Knowledge - Impacting Health

HOME ABOUT RESEARCH SCIENTIFIC PUBLICATIONS MEDIA NEWSLETTERS CAREERS FELLOWSHIP PROGRAMME ALUMNI CONTACT

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS

Prestigious scholarship for CAPRISA Research Placement

30 August 2019

CAPRISA congratulates Kapil Narain, a CAPRISA Research Placement and a fifth-year medical student at UKZN, who is one of four students selected globally as a recipient of the Changemaker Scholarship programme funded by the Alliance for Health Systems and Policy at the WHO. Narain attended the 72nd World Health Assembly (WHA) and the IFMSA Youth Pre- World Health Assembly workshop (PreWHA) in Geneva, Switzerland . He said that meeting Dr Tedros Adhanom Ghebreyesus, Director-General of the WHO was a highlight.

Narain said he was honoured to be part of CAPRISA and "each and every day I am constantly inspired and stimulated by the sheer degree of scientific rigour, novelty, clinical relevance and Innovation."



World Health Organization



Fig: Kapil Narain, CAPRISA Research Placement with Dr Tedros Adhanom Ghebreyesus, DG of Health in Geneva

Karim's CAPRISA ties to the Global Elite

Study Sponsor



Co-Funders



National Institute
of Allergy and
Infectious Diseases

BILL & MELINDA
GATES *foundation*

NIH and Partners Launch HIV Vaccine Efficacy Study

Public-Private Partnership Begins Clinical Trial in Sub-Saharan Africa

November 30, 2017

The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection. The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent occurred in eastern and southern Africa, with women and girls disproportionately affected.

"Imbokodo," the Zulu word for rock, is part of a well-known proverb in South Africa that refers to the strength of women and their importance in the community. The study is sponsored by Janssen Vaccines & Prevention, B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, with co-funding from two primary partners, the Bill & Melinda Gates Foundation (BMGF) and NIH's National Institute of Allergy and Infectious Diseases (NIAID).

Karim's CAPRISA ties to the Global Elite



HVTN 702: A **pivotal** phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa



Glenda Gray (Chair)
Linda-Gail Bekker (Co-chair)
Kathy Mngadi (PI for CAPRISA Durban ECRS)



Study Leaders



Prof Glenda Gray,
Chair Imbokodo Study




Prof Linda-Gail
Bekker, Co-chair



Dr Kathryn Mngadi,
PI for CAPRISA

Karim's CAPRISA ties to the Global Elite



National Institute
of Allergy and
Infectious Diseases



Dr. Anthony Fauci, Director NIAID



**Prof Salim Abdool Karim, Director
CAPRISA**

First New HIV Vaccine Efficacy Study in Seven Years Has Begun

South Africa Hosts Historic NIH-Supported Clinical Trial

November 27, 2016

[Read the Related Questions & Answers](#)

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day.

“If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health and a co-funder of the trial. “Even a

Karim's CAPRISA ties to the Global Elite



National Institutes of Health
Turning Discovery Into Health

[HOME](#) [ABOUT](#) [RESEARCH](#) [SCIENTIFIC PUBLICATIONS](#) [MEDIA](#) [NEWSLETTERS](#) [CAREERS](#) [FELLOWSHIP PROGRAMME](#) [ALUMNI](#)

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS

NIH funded Grant Administration workshop

31 October 2017



Participants at the Grant Administration workshop. This NIH-funded workshop was hosted by CAPRISA in partnership with the Centre for Infectious Disease Research in Zambia (CIDRZ). Research administration staff from CIDRZ, UKZN and Walter Sisulu University participated in the two day workshop held at the CAPRISA headquarters on 16 and 17 October. Selected candidates from CIDRZ also participated in an internship programme at CAPRISA and will receive ongoing mentorship in grants administration.

<https://www.caprisa.org/NewsAndEvents/Read/10197>

24th February 2021

The Honourable Minister Dr Zweli Mkhize
Minister of Health
Republic of South Africa
Private Bag X828, PRETORIA
0001

Dear Minister Mkhize

Re: End of the Term of Office on the Ministerial Advisory Committee on Covid-19

It has been my singular honour and privilege to serve as the Chair initially and subsequently as the co-Chair of the Ministerial Advisory Committee on Covid-19 during an unprecedented time in our country's history. When I accepted the appointment on 23 March 2020, little did I realise how important science would be in helping our country navigate the complexities of the Coronavirus pandemic. It has been most rewarding, to work alongside many of our country's leading scientists from a range of disciplines - South Africa is indeed very fortunate to have so many accomplished scientists in the MAC.

As the one-year anniversary of my term nears, the time has come for me to return to my HIV research and my academic commitments. I am therefore stepping down from the MAC on Covid-19 (and consequently from the MAC Vaccines as well), having served for a year, with my last day being 23rd March 2021.

The MAC is well set to continue its good work and to rise to the challenges of dealing with Covid-19. I have been thoroughly impressed with the skills, dedication and commitment of the MAC members and so, I leave knowing full well that advice on our Covid-19 response is in safe hands. I wish to pay tribute to my colleagues who served and who continue to serve on the MAC – it is a labour of love, grappling with an avalanche of new information daily – sifting through fact, fiction, conspiracy theories, assumptions and projections to provide science-based advice in the midst of substantial uncertainty. I also wish to acknowledge the significant contributions and expertise of the MAC secretariat who worked tirelessly behind the scenes providing invaluable support.

From April, I will be re-focusing on my HIV research, especially on broadly neutralising antibodies for HIV prevention, which is a critical stage but has slowed as I have not been able to devote time and effort to it. It has been deeply disappointing to see how little progress we have made in the last few years in preventing HIV in young women in Africa. The novel antibody technologies we have developed could make an important contribution to bringing the global effort of HIV prevention back on track. I will of course remain available to assist the MAC on Covid-19 as and when required and I will ensure that I complete my current



Scientific Advisory Committee Member

Salim S. Abdool Karim, M.B.Ch.B, Dip.Data (computer science), M.S., M.Med, F.F.P.H.M., Ph.D., D.Sc.(hc)

Salim S. Abdool Karim is a South African clinical infectious diseases epidemiologist who is widely recognized for his research contributions in HIV prevention and treatment. He is director of the Centre for the AIDS Program of Research in South Africa (CAPRISA) and CAPRISA professor of global health at Columbia University. He is also pro vice-chancellor (research) at the University of KwaZulu-Natal, South Africa, and adjunct professor of medicine at Cornell University in New York. He has served as the president of the South African Medical Research Council and is an associate member of the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard University.

His clinical research on tuberculosis-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He was co-leader of the CAPRISA 004 tenofovir gel trial that provided proof-of-concept that antiretrovirals can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents that have been used in several HIV vaccine candidates and in passive immunization strategies with broadly neutralizing antibodies.

Abdool Karim is chair of the UNAIDS Scientific Expert Panel, WHO's HIV Strategic and Technical Advisory Committee, and the WHO Tuberculosis-HIV Task Force. He serves on the boards of several journals, including the New England Journal of Medicine, Lancet Global Health, Lancet HIV, and mBio. He is a member of the Royal Society of South Africa, Academy of Science of South Africa, African Academy of Sciences, and the World Academy of Sciences (TWAS). He is a member of the U.S. National Academy of Medicine, the American Academy of Microbiology, and the Association of American Physicians.

His awards include the TWAS Prize in Medical Sciences, the African Academy of Science's Olusegun Obasanjo Prize for Scientific Discovery and Technological Innovation, the Science for Society Gold Medal Award from the Academy of Science in South Africa, the Platinum Medal Lifetime Achievement Award from the South African Medical Research Council, and Columbia University's Allan Rosenfield Alumni Award for Excellence. The African Union awarded him the Kwame Nkrumah Continental Scientific Award, the most prestigious scientific award in Africa.



Prof Salim Abdool Karim, Director of the Centre for Aids Programme Research in South Africa (CAPRISA)

Is this how much Salim gets paid?

Bill & Melinda Gates Foundation Senior Advisor Salaries

 Low Confidence

1 Salary Updated May 4, 2018

Location

United States

All Years of Experience

Any Experience

Search

Base Pay
\$245K - \$268K



Additional Pay
No Reports



CAPRISA hosts senior officials from the Gates Foundation
2 August 2015

From left to right: Professor Salim Abdool Karim, Director of CAPRISA, welcomes Dr Emilio Emini, Dr David Allen (left back), Gates Foundation country representative in South Africa, and Professor Geoff Garnett, Deputy Director of HIV for the Global Health Program, to CAPRISA.



funding



GRANT

← BACK

 Print

CAPRISA

Date: July 2016

Purpose: to develop practical approaches to amplifying the voice, and incorporating the perspective, of African thought-leaders and stakeholders in global health research and development

Amount: \$1,233,758

Term: 47

Topic: Discovery and Translational Sciences, Malaria

Program: Global Health

Grantee Location: Durban, KwaZulu-Natal

Grantee Website: <http://www.caprisa.org>

Karim's ties to the Global Elite



Generating Knowledge - Impacting Health

[HOME](#) [ABOUT US](#) [RESEARCH](#) [SCIENTIFIC PUBLICATIONS](#) [MEDIA](#) [NEWSLETTERS](#) [CAREERS](#) [CONTACT](#)

[Home](#) / [Media](#) / [News and Events](#)

LATEST NEWS AND EVENTS

Gates Foundation funds ethics study

25 August 2016



Share this article:

A grant “to develop and articulate African (“Southern”) perspectives on the ethical, legal, social, and cultural implications of synthetic biology, and in particular, gene drive applications,” was awarded by the Bill and Melinda Gates Foundation to Professor Jerome Singh, Head of Ethics at CAPRISA.

The grant, a total of \$402,000 over a two year period, will “enable the articulation of African perspectives on synthetic biology, especially in regard to gene drive applications. Drawing on indigenous African knowledge systems, such articulation will allow for the ex-pression of indigenous, contextual, and nuanced Southern perspectives on synthetic biology, specifically, gene drive applications,” explained Prof Singh.

Archives

Latest Posts

2021
2020
2019
2018
2017
2016
2015
2014
2013

Gates Foundation features on CAPRISA



HOME ABOUT US RESEARCH SCIENTIFIC PUBLICATIONS MEDIA NEWSLETTERS CARE

Home / Media / Videos

VIDEOS



Grand Challenges Spotlight Talk I: Salim Abdool Karim

Health



nature

2020 John Maddox prize awarded to Anthony Fauci and Salim Abdool Karim



Bill Gates's Heroes in the Field: Drs. Quarraisha and Salim Abdool Karim



CAPRISA video Gates Ventures Final

Karim's ties to the Global Elite



No Introduction Required



Fig. Mr Bill Gates and senior officials of the Bill and Melinda Gates Foundation visited CAPRISA's headquarters and the CAPRISA eThekweni Research Clinic on 19 July 2016. L-R: Prof Salim Abdool Karim, Dr Trevor Mundel, President of the Global Health Division, Mr Bill Gates, Dr Nesri Padayatchi from CAPRISA and Dr Emilio Emini, Director of HIV, Global Health program during Mr Gates's visit to the Clinic.



Fig. Dr Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes for Health, visited the CAPRISA Vulindlela Research Clinic on 18 July 2016. He also visited the CAPRISA eThekweni Research Clinic and CAPRISA headquarters on 20th July where he met with several of CAPRISA's scientists including: back row (L-R): Dr Aida Sivro, Dr Leila Mansoor, Dr Kathy Mngadi, Prof Ayesha Kharsany, Ms Yajna Duki, Dr Lenine Liebenberg, Dr Kogie Naidoo, Dr Tanuja Gengiah, Dr Desh Archary, Dr Carl Montague. Front Row (L-R): Dr Nesri Padayatchi, Dr Gray Handley, Dr Anthony Fauci and Prof Salim Abdool Karim.

Karim's ties to the Global Elite



Prof Salim Abdool Karim, Director CAPRISA

Karim's ties to the Global Elite



Bill Gates and the South African Ministerial Advisory Committee on COVID-19

Researcher	Institution	Role in MAC	Sub Funder	Principal Funder
Prof Salim Abdool Karim	CAPRISA	OVER-ARCHING CHAIR	USAID via Concord WHO TB-HIV task force	Bill and Melinda Gates Foundation (BMGF)
Prof Quraisha Abdool Karim	CAPRISA	Public Health		BMGF
Prof Helen Rees	South African Health Products Regulatory Authority (SAHPRA)	Clinicians	WHO, Co-Chair Ebola Vaccine	BMGF
Prof Lynn Morris	National Institute for Communicable Diseases (NICD)	Pathologists and Laboratory		BMGF
Prof Wolfgang Preiser	National Health Laboratory Service	Pathologists and Laboratory		BMGF
Prof Wendy Stevens	National Health Laboratory Service	Pathologists and Laboratory		BMGF
Prof Shabir Madhi	SAMRC	CHAIR, Public Health	WHO, Consultant	BMGF, Consultant
Prof Glenda Gray	SAMRC	CHAIR, Research	NIH, Wellcome Trust	BMGF
Prof Marc Mendelson	University of Cape Town	CHAIR, Clinicians	WHO	BMGF
Dr Moherndran Archary	University of KwaZulu-Natal	Clinicians		BMGF
Prof Shabir Banoo	Right to Care	Clinicians	WHO	BMGF



Scientific Advisory Committee Member

Shabir A. Madhi, M.B.B.C.H., FCPaeds, Ph.D.

Shabir Madhi is professor of vaccinology at the University of the Witwatersrand in Johannesburg. He also holds the positions of director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit and he is research chair in vaccine preventable diseases at the Department of Science and Technology at the National Research Foundation. He is the immediate past director of the National Institute for Communicable Diseases (2011 to 2017), and he currently serves as the chair of the National Advisory Group on Immunization in South Africa.

Author of more than 350 scientific publications, his research focus has been on epidemiology and clinical development of vaccines against pneumonia, diarrheal disease, and for maternal immunization. These studies have been pivotal to informing WHO and SAGE policy on the use of such vaccines in low-middle income countries. He has served as a temporary consultant/technical adviser to WHO in the field of pneumonia and vaccines.



**Prof Shabir A. Mahdi, Prof of Vaccinology,
Univ. Witwatersrand. Research Chair at
Dept. of Science and Technology, SA.**

Karim inducted into the Royal Elite: The Royal Society and Freemasonry



Prof Shabir Mahdi, Royal Society of SA (RSSf) fellow



Freemasonry

**The Royal Society
subverted Science**

The Royal Society was founded by Freemasons. Sir Robert Moray, Grand Master of Freemasonry in England and founder of the Royal Society is said to be the guiding spirit behind the society even today. John Theophilus Desaguliers, the Grand Master and Father of Modern Freemasonry was a Royal Society Fellow. Sir Isaac Newton, Father of Mechanics, was a prominent Freemason and the President of the Royal Society. The Royal Society operates within the fundamental bounds of its original Masonic founders

Vaccinology in sub-Saharan Africa

Jennifer Moïsi,¹ Shabir Ahmed Madhi,^{2,3} Helen Rees^{3,4}



To cite: Moïsi J, Madhi SA, Rees H. Vaccinology in sub-Saharan Africa. *BMJ Global Health* 2019;4:e001363. doi:10.1136/bmjgh-2018-001363

Handling editor Dr Seye Abimbola

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2018-001363>)

Received 13 December 2018
Revised 13 June 2019

ABSTRACT

We undertook a landscape analysis of vaccinology research and training in sub-Saharan Africa in order to identify key gaps and opportunities for capacity development in the field. We conducted interviews with regional and global immunisation experts, reviewed university and research centre websites, searched the scientific literature and analysed donor databases as part of our mapping exercise. We found that (1) few vaccinology training programmes are available in the region; (2) vaccinology research sites are numerous but unevenly distributed across countries and subregions and of widely varying capacity; (3) donor funding favours HIV, tuberculosis and malaria vaccine development over other high-burden diseases; (4) lack of vaccine design, manufacturing and regulatory capacity slows the progress of new vaccines through the research and development

Contributors SAM and HR developed the study concept; provided critical input to study conduct, contributed to data interpretation and reviewed the manuscript. JCM designed the study methodology, collected and analysed the data and wrote the first draft of the manuscript.

Funding This study was funded by [The Bill and Melinda Gates Foundation](#).

Competing interests JCM was an independent consultant at the time the study was conducted. Previously, she worked for Agence de Médecine Préventive, where she received research funding from Pfizer and GSK. She is now an employee of Pfizer Vaccines. [SAM receives research funding from Pfizer, GSK, Novartis and Biovac.](#)

[Health Topics](#) ▾[Countries](#) ▾[Newsroom](#) ▾[Emergencies](#) ▾[Data](#) ▾[About Us](#) ▾

Strategic Advisory Group of Experts on Immunization, Vaccines and Biologicals (SAGE)



Bernard Fritzell, M.D., M.P.H. former Vice-President, International Scientific and Clinical Affairs, Pfizer Vaccines Research



Barney S. Graham, M.D., PhD Senior Investigator at the Vaccine Research Center, NIAID, NIH



Ruth Karron, M.D. CDC Advisory Committee on Immunization Practices. FDA Vaccine and Related Biological Products Advisory Committee




David C. Kaslow, M.D. Vice President, Essential Medicines, and Head, PATH's Center for Vaccine Innovation and Access Vice President and Head of Vaccines Project Leadership and Management at Merck Research Laboratories National Institute of Allergy and Infectious Diseases (NIAID)



Jerome H. Kim, M.D., Director General of the International Vaccine Institute (IVI) funded by Bill and Melinda Gates Foundation.



Prof. Shabir Madhi, Prof Vaccinology, Wits Univ. Head of SA AstraZeneca ChAdOx1 Trial, Chair of the National Advisory Group for Immunization in South Africa and on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation Global Health Program.





University of the Witwatersrand

WITS RHI

Wits Reproductive Health and HIV Institute and Prof Helen Rees

Conflicts of Interest



Founder & Director
of Wits RHI

Donors & Partners



THE AURUM
INSTITUTE



UNIVERSITY OF THE
WITWATERSRAND
JOHANNESBURG



**“A nation of sheep
will soon have a
government of
wolves”**

The Motsepe-Ramaphosa Axis of Power”



Patrice Motsepe

Dr Precious Moloi-Motsepe





Minister Jeff Radebe

Bridgette Motsepe-Radebe



President Cyril Ramaphosa



The Motsepe-Ramaphosa Axis of Power and the Global Elite

World Economic Forum Appoints Two New Members to Board of Trustees



Patrice Motsepe

Chairman of African Rainbow Minerals

Geneva, Switzerland, 24 January 2020– Kristalina Georgieva, Managing Director at the International Monetary Fund (IMF) and Patrice Motsepe, Founder and Executive Chairman, African Rainbow Minerals (ARM), will join the Board of Trustees of the World Economic Forum. Both have a track record of thought leadership and long-term success in their field, which will contribute to strengthening the Forum's platform for public-private cooperation.

Patrice Motsepe, Founder and Executive Chairman, African Rainbow Minerals a global diversified mining company, South Africa; Former Partner, Attorneys Bowmans, South Africa; Visiting Attorney, McGuireWoods, Virginia, US. Founder, ARMgold. Non-Executive Chairman, Harmony Gold Mining Company. Deputy Chairman, Sanlam. Founding President, BUSA (Business Unity South Africa). Chairman, BRICS Business Council 2013. Former member, JP Morgan International Council. Member, International Business Council and Global Leader for Tomorrow, World Economic Forum. Member, Harvard Global Advisory Council. Awards: South Africa's Business Leader of the Year, voted by CEOs of South Africa's top 100 companies (2002); South Africa's Best Entrepreneur of the Year, Ernst & Young (2002).

World Economic Forum: Board of Trustees – The Global Elite and Hencemen



Mukesh D. Ambani

Chairman and Managing Director, Reliance Industries



Marc Benioff

Chair and Co-Chief Executive Officer, Salesforce



Peter Maurer

President, International Committee of the Red Cross (ICRC)



Luis Alberto Moreno

Managing Director, Allen & Company



Peter Brabeck-Letmathe

Vice-Chairman of the Board of Trustees, World Economic Forum



Thomas Buberl

Chief Executive Officer, AXA



Patrice Motsepe

Founder and Executive Chairman, African Rainbow Minerals



Ngozi Okonjo-Iweala

Director-General, World Trade Organization (WTO)



Mark Carney

United Nations Special Envoy for Climate Action and Finance, United Nations



Laurence D. Fink

Chairman and Chief Executive Officer, BlackRock



H.M. Queen Rania Al Abdullah of the Hashemite Kingdom of Jordan

Queen of the Hashemite Kingdom of Jordan, Office of Her Majesty Queen Rania Al Abdullah



L. Rafael Reif

President, Massachusetts Institute of Technology



Chrystia Freeland

Deputy Prime Minister and Minister of Finance, Office of the Deputy Prime Minister of Canada



Orit Gadiesh

Chairman, Bain & Company



David M. Rubenstein

Co-Founder and Co-Chairman, Carlyle



Mark Schneider

Chief Executive Officer, Nestlé



Kristalina Georgieva

Managing Director, International Monetary Fund (IMF)



Fabiola Gianotti

Director-General, European Organization for Nuclear Research (CERN)



Klaus Schwab

Founder and Executive Chairman, World Economic Forum



Tharman Shanmugaratnam

Senior Minister, Government of Singapore



Al Gore

Vice-President of the United States (1993-2001); Chairman and Co-Founder, Generation Investment Management LLP



Herman Gref

Chief Executive Officer and Chairman of the Board, Sberbank



Jim Hagemann Snaab

Chairman, Siemens



Julie Sweet

Chair and Chief Executive Officer, Accenture



Andre Hoffmann

Chairman, Massellaz



Paula Ingabire

Minister of Information Communication Technology and Innovation, Ministry of Information Communication Technology and Innovation of Rwanda



Feike Sybesma

Chairman of the Supervisory Board, Royal Philips



Heizo Takenaka

Professor Emeritus, Keio University



Christine Lagarde

President, European Central Bank



Yo-Yo Ma

Cellist,




Zhu Min

Chairman, National Institute of Financial Research



Patrice Motsepe: SA Elite joins the Global Cabal



Patrice Motsepe: SA Elite joins the Global Cabal

2015 World Economic Forum on Africa

Cape Town, South Africa, 3-5 June 2015



COMMITTED TO
IMPROVING THE STATE
OF THE WORLD

Co-Chairs :

- **Antony Jenkins**, Group Chief Executive, Barclays, United Kingdom
- **Phumzile Mlambo-Ngcuka**, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN), New York
- **Patrice Motsepe**, Founder and Executive Chairman, African Rainbow Minerals, South Africa
- **Paul Polman**, Chief Executive Officer, Unilever, United Kingdom
- **Michael Rake**, Chairman, BT Group, United Kingdom



Patrice Motsepe
Executive Chairman of African
Rainbow Minerals

Patrice Motsepe: SA Elite joins the Global Cabal

Board of Trustees



Name	Position	Company and Designation
Klaus SCHWAB	Chairman of the Board of Trustees	World Economic Forum
Peter BRABECK-LETMATHE	Vice-Chairman	Nestlé SA, Chairman
Orit GADIESH	Member, Audit & Risk Committee	Chairman, Bain & Company, USA
André S. HOFFMANN	Member of the Governing Board	Roche Holding Ltd., Switzerland. Non-Executive Vice-Chairman
Laurence FINK	Member	BlackRock, Chairman and CEO, USA
Christine LAGARDE		President, European Central Bank
Patrice MOTSEPE	Member	African Rainbow Minerals, Founder and Executive Chairman, South Africa
Jim Hagemann SNABE	Member, Audit & Risk Committee	Siemens AG, Germany
Kristalina GEORGIEVA,	Member	Managing Director, International Monetary Fund
Al GORE	Member	Generation Investment Management LLP, USA. Chairman and Co-Founder
H.M. Queen Rania AL ABDULLAH	Member	Hashemite Kingdom of Jordan
Angel GURRÍA	Member of the Governing Board	Organisation for Economic Co-operation and Development, Secretary-General

Patrice Motsepe: SA Elite joins the Global Cabal

● Live The Davos Agenda Watch now >

Strategic Partner

African Rainbow Minerals

African Rainbow Minerals (ARM) is a leading diversified South African mining and minerals company with long-life, low unit cost operations and significant growth opportunities. ARM mines iron ore, manganese ore and alloys, chrome ore and alloys, platinum group metals, copper, nickel and coal. The company also has an investment in gold through its shareholding in Harmony. ARM is committed to responsible environmental stewardship as a fundamental part of sustainable value creation.

[Visit the African Rainbow Minerals website](#) →



Headquarters
South Africa

Patrice Motsepe: SA Elite joins the Global Cabal



Schwab Foundation for Social Entrepreneurship in partnership with the World Economic Forum.

© Copyright World Economic Forum — Privacy Policy & Terms of Service

fin24

Search



HOME

FOR SUBSCRIBERS

COMPANIES

ECONOMY ▾

MARKETS ▾

OPINION

MONEY

TECH

🕒 04 Jun 2015



Motsepes in multi-million rand social entrepreneur pact

SHARE



Cape Town – World Economic Forum (WEF) executive chair Klaus Schwab and WEF on Africa co-chair Patrice Motsepe might be the big names of the forum, but their wives had a moment in the sun on Thursday when they announced plans to stimulate social entrepreneurship in Africa.

Dr Precious Moloi-Motsepe and Hilde Schwab held a press conference at the forum to announce the launch of a million Swiss franc (R13.24m) partnership between the Schwab Foundation for Social Entrepreneurship and the Motsepe Foundation.

Patrice Motsepe: SA Elite joins the Global Cabal



Fig: Patrice Motsepe (right), Mr Nicholas Oppenheimer (Anglo-American Corp)

Cyril Ramaphosa: SA Elite joins the Global Cabal



Cyril Ramaphosa: SA Elite joins the Global Cabal



SA President serving the interests of the Global Elite



**Judged by the
company you
keep!!!**

SA President serving the interests of the Local Elite



**Judged by the
company you
keep!!!**

How Cyril Ramaphosa Sold His Soul to The Oppenheims For \$900 Million. How Much Will He Sell SA For?

Harry Oppenheimer held his 1st meet with Cyril Ramaphosa on 29 November 1976, at the Carlton Hotel Johannesburg.

In 1995, Johnnic Holdings Limited, an Anglo American Corporation subsidiary was valued at \$1.88 billion/8.5 billion Rand.

1995, Oppenheimer vendor financed Ramaphosa's 1st JSE listed "BBBEE" US\$500 million deal, in partnership with Phuthumani Nhleko to purchase Johnnic Ltd, a media company publishing Sunday Times, Sowetan etc from Oppenheimer's corp Anglo American

It carved up Johannesburg Consolidated Investments (JCI) to sell Johnnic and JCI to the National Empowerment Consortium and African Mining Group. Johnnic sold 48% stake to National Empowerment Consortium led by Cyril Ramaphosa



Fig. Cyril Ramaphosa, with the late Harry Oppenheimer in this 1986 photograph at the first anniversary celebration of The Weekly Mail newspaper, where they met. (PHOTO: Robert Botha)

Judged by the Company you keep?



Fig. George Soros (left) and SA President, Cyril Ramaphosa (right)

Judged by the Company you keep?



Very bad news for faith, family, and religious freedoms in South Africa President Cyril Ramaphosa in a desperate bid to raise billions in investments met with US billionaire, George Soros and his son in New York recently. Soros is evil incarnate. He funds the global sexual rights movement, the abortion Holocaust, and decriminalised prostitution. However, Soros' attacks on religious freedoms are most disturbing. If the Gupta family could capture the ANC, imagine what this wicked man could achieve with his tens of billions of US dollars. The ANC/Soros partnership therefore is truly a match made in hell.



George Soros & Ramaphosa –
ONAFHANKLIK

Visit



South African Government



@GovernmentZA

President Cyril Ramaphosa meeting Mr George Soros and his son, Alexander Soros, during a bilateral meeting at the Intercontinental Hotel in New York. Mr Soros is a Hungarian-American investor, business magnate, philanthropist, political activist and author. #UNGA18 #UNGA



5:41 PM · Sep 27, 2018



66



38



Copy link to Tweet

SA Government captured by the Global Elite



Fig. Nelson Mandela and Klaus Schwab, Davos 1999

SA President serving the interests of the Global Elite



**Judged by the
company you
keep!!!**

SA President serving the interests of the Global Elite



Fig. Nelson Mandela with Anglo American chief Harry Oppenheimer in February 1994. (Photo : Gallo Images / Avusa)

The Motsepe-Ramaphosa Axis of Power and the Global Elite

[Join us](#)[Sign in](#)

Precious Moloi-Motsepe

Co-Founder and Chief Executive Officer, Motsepe Foundation

Businesswoman and Philanthropist, Chancellor University of Cape Town (UCT), professional background as a medical doctor. Executive Chairman and Founder of African Fashion International, a social enterprise establishment to promote the creative industry and create jobs for women and youth. Co-Chair and Chief Executive Officer, The Motsepe Foundation; its founding vision is to improve the quality of life for all, by promoting respect for diversity and supporting projects have the potential to assist beneficiaries in becoming self-reliant with programmes in education and leadership, sports, music and arts, community development, a Centre for Gender Equality and Leadership. It works with stakeholders and governments on initiatives to promote social cohesion. With her husband, was the first African couple to join the Giving Pledge and as co-investors of the Breakthrough Energy Venture. Member: The Harvard Kennedy School Women's Leadership Board and Public Leadership Council. Former President, Cancer Association for South Africa. Co-Chair, Maverick Collective USA. Interest/Passion : Education, Youth Development ,Gender Equality, women empowerment, Health and Wellness.

The Motsepe-Ramaphosa Axis of Power and the Global Elite



BOARD MEMBERS



Professor Shabir Madhi
Chairman and Non-Executive Director



Prof Helen Rees
Founder and Chief Executive Director



Tsepho Motsepe (nee Ramaphosa)
A non-executive director

South African Universities and the Gates Foundation influence

South African Universities and Gates Foundation influence

BILL & MELINDA
GATES foundation

Committed grants

Grantee

**Wits Health
Consortium
(Pty) Ltd**



Grant Topic	Commencement Date	Committed Amount
Pneumonia	JANUARY 2022	\$318,502
Pneumonia	NOVEMBER 2021	\$3,004,775
Support Innovative Technology Solutions	NOVEMBER 2021	\$8,777,433
Tuberculosis	NOVEMBER 2021	\$899,899
HIV	NOVEMBER 2021	\$218,805
Vaccine Development	OCTOBER 2021	\$180,282
Pneumonia	MAY 2021	\$2,300,010
Development of Solutions to Improve Global Health	FEBRUARY 2021	\$1,453,490
Vaccine Development	AUGUST 2020	\$881,394
MNCH Discovery and Tools	JUNE 2020	\$1,999,889
Development of Solutions	JUNE 2019	\$3,140,019
Development of Solutions	APRIL 2019	\$1,360,784
Pneumonia	OCTOBER 2018	\$2,714,626
Pneumonia	APRIL 2018	\$1,893,025
Pneumonia	MAY 2017	\$299,116
Pneumonia	NOVEMBER 2016	\$723,400
Pneumonia	JUNE 2016	\$2,345,050
Malaria	NOVEMBER 2015	\$262,337
Pneumonia	OCTOBER 2014	\$3,060,440
Pneumonia	OCTOBER 2014	\$5,408,262
HIV	OCTOBER 2013	\$1,416,863

South African Universities and Gates Foundation influence

BILL & MELINDA
GATES foundation

Committed grants

Grantee

University of Cape Town



Grant Topic	Commencement Date	Committed Amount
MNCH Discovery and Tools	NOVEMBER 2021	\$75,643
Discovery and Translational Sciences	OCTOBER 2021	\$1,227,636
MNCH Discovery and Tools	JULY 2021	\$200,000
MNCH Discovery and Tools	NOVEMBER 2020	\$75,400
Vaccine Development	NOVEMBER 2020	\$497,062
HIV	SEPTEMBER 2020	\$1,412,504
MNCH Discovery and Tools	SEPTEMBER 2020	\$399,226
Tuberculosis	NOVEMBER 2017	\$2,645,147
HIV	NOVEMBER 2016	\$8,473,787
Tuberculosis	NOVEMBER 2015	\$249,387
Tuberculosis	OCTOBER 2014	\$1,999,951
Tuberculosis	OCTOBER 2014	\$223,577
Tuberculosis	JULY 2014	\$340,419
Tuberculosis	OCTOBER 2013	\$508,471
Enteric and Diarrheal Diseases	MARCH 2012	\$50,275



&



South African Universities and Gates Foundation influence

Purpose

To support pathogen genomics data standards and bioinformatics interoperability

DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Global Health	NOVEMBER 2021	GLOBAL, AFRICA, NORTH AMERICA	\$1,080,330
GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Vaccine Development	22	Belville, South Africa	

Purpose

To support the development of extraordinary scientists and emerging leaders from low and middle income countries in order to ensure transformative solutions fully deliver impact in geographies we serve

DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Global Health	OCTOBER 2021	GLOBAL, AFRICA	\$968,546
GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Discovery and Translational Sciences	61	Belville, South Africa	

South African Universities and Gates Foundation influence



University of the Western Cape
School of Public Health



UNIVERSITY of the
WESTERN CAPE

BILL & MELINDA
GATES foundation

Gender and Health Hub

Project period

01 January 2021 – 31 December 2022

In 2019 UWC entered into a memorandum of understanding (MoU) with United Nations University International Institute for Global Health (UNU-IIGH) to work together on advancing research and policy on gender and health from a global South perspective.

SOPH's Asha George is a member of the Core Working Group for the [Gender and Health Hub](#) funded by the Bill and Melinda Gates Foundation. Under this MoU, SOPH will support gender and health activities in sub-Saharan Africa and undertake gender analysis in health systems (primary health care, human resources for health).

As a part of this collaboration, Asha George led the analysis on violence against women health workers as a part of the [BMJ Series on Women's Health and Gender Inequalities](#) co-edited by WHO and UNU-IIGH.

UWC has been co-convening an open and consultative process to set research priorities on Gender and COVID-19. Since September 2020, over 400 participants, mostly from low- and middle-income country settings have been engaged, a research protocol finalised and five thematic reports drafted.

Funder

- Bill and Melinda Gates Foundation through United Nations University International Institute for Global Health (UNU-IIGH)

South African Universities and Gates Foundation influence

BILL & MELINDA
GATES *foundation*

Committed grants



UNIVERSITEIT
STELLENBOSCH
UNIVERSITY

Grant Topic	Date	Committed Amount
Tuberculosis	NOVEMBER 2020	\$504,814
Support Innovative Technology Solutions	JUNE 2019	\$246,387
Tuberculosis	SEPTEMBER 2018	\$996,318
Tuberculosis	JUNE 2018	\$2,130,199
Discovery and Translational Sciences	OCTOBER 2017	\$100,000
HIV	NOVEMBER 2013	\$183,235
Tuberculosis	SEPTEMBER 2011	\$898,225
Tuberculosis	SEPTEMBER 2008	\$1,566,649

South African Universities and Gates Foundation influence

BILL & MELINDA
GATES foundation

Committed grants



Grant Topic	Date	Committed Amount
Discovery and Translational Sciences	OCTOBER 2021	\$187,454
Discovery and Translational Sciences	OCTOBER 2020	\$512,088
Discovery and Translational Sciences	JULY 2016	\$1,233,758



Grant Topic	Date	Committed Amount
HIV	JUNE 2019	\$1,150,000

South African Universities and Gates Foundation Committed Grants

BILL & MELINDA
GATES *foundation*

Grantee: University of Pretoria



Grant Topic	Date Issued	Committed Grant Amount
MNCH Discovery and Tools	MARCH 2022	\$416,218
Agricultural Development	NOVEMBER 2021	\$550,287
Malaria	OCTOBER 2021	\$845,964
MNCH Discovery and Tools	FEBRUARY 2021	\$192,903
Discovery and Translational Sciences	APRIL 2012	\$100,000
Agricultural Development	MAY 2011	\$4,475,287
Discovery and Translational Sciences	MAY 2009	\$100,000

South African Universities and Gates Foundation influence and Committed Grants

BILL & MELINDA
GATES *foundation*

Committed grants

GRANTEE

University of the
Free State



DIVISION

Global Health

GRANT TOPIC

Enteric and Diarrheal
Diseases

DATE

NOVEMBER 2017

DURATION (MONTHS)

52

REGION SERVED

GLOBAL +1

GRANTEE LOCATION

Bloemfontein, Free State,
South Africa

COMMITTED AMOUNT

\$965,798

South African Universities and Gates Foundation influence

Committed Grants


BILL & MELINDA
GATES *foundation*

Grantee	Grant Topic	Date Issued	Grant Amount
Durban University of Technology	Neglected Tropical Diseases	JANUARY 2015	\$385,363
UNISA	Global Libraries	APRIL 2013	\$125,000
UNISA	Global Libraries	APRIL 2011	\$91,320
University of Limpopo	Enteric and Diarrheal Diseases	JULY 2012	\$60,000
Tshwane University	Agricultural Development	NOVEMBER 2011	\$1,279,771

Fudging the Stats – SA and Bill Gates

COVID-19 IN SOUTH AFRICA

INITIAL PROJECTED RATE OF INFECTIONS,
HOSPITALISATIONS AND DEATHS



PROJECTED DEATHS ASSOCIATED WITH COVID-19

10% - 87 900 20% - 176 000 40% - 351 000

**Projections contained in this graphic are a representation of early estimates and rudimentary calculations, compiled using static data based on what is known of COVID-19 spread in other areas. The projections are subject to change as new information becomes available.*


Data: SACEMA

Graphic: Kyle Cowan for News24

South African COVID-19 Modelling Consortium



South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis, University of Stellenbosch. Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)



Health Economics and Epidemiology Research Office, University of Witwatersrand. AMBIT is a 2.5-year research and evaluation project



Modelling and Simulation Hub Africa, University of Cape Town.



Boston University School of Public Health, USA. AMBIT is a 2.5-year research and evaluation project



National Institute For Communicable Diseases, South Africa. Grand Challenges in Global Health initiative

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University and Bill and Melinda Gates Foundation



Stellenbosch
UNIVERSITY
IYUNIVESITHI
UNIVERSITEIT



BILL & MELINDA
GATES foundation

Publication Title	Author	Article Details	Funder
Population-level HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches in KwaZulu-Natal, South Africa	Eduard Grebe, Alex Welte	PLoS ONE 13(9), https://doi.org/10.1371/journal.pone.0203638	Bill and Melinda Gates Foundation (BMGF)
Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models	Daniel Keebler	Lancet Glob Health, 2014 Jan;2(1):e35-43. doi: 10.1016/S2214-109X(13)70048-2.	BMGF
Early mortality in tuberculosis patients initially lost to follow up following diagnosis in provincial hospitals and primary health care facilities in Western Cape, South Africa	Alex Welte	PLoS ONE 16(6): e0252084. June 14, 2021, https://doi.org/10.1371/journal.pone.0252084	BMGF, US National Institutes for Health
COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness	Carl A. B. Pearson	https://doi.org/10.1371/journal.pmed.1003815	BMGF, Wellcome Trust
Key questions for modelling COVID-19 exit strategies	Juliet R. C. Pulliam, Carl A. B. Pearson	https://royalsocietypublishing.org/doi/10.1098/rspb.2020.1405	BMGF, Wellcome Trust

Modelling and Simulation Hub (MASHA), UCT, South Africa and the Gates Foundation



Modelling and Simulation Hub Africa



Catastrophic predictions: 40 000 to 45 000 South Africans could die from Covid-19 between June and November, 2020 and that one million South Africans would become infected.



This is a project of the Bill and Melinda Gates Foundation

Modelling and Simulation Hub Africa (MASHA), University of Cape Town and Gates Foundation

Journal Title	Author	Article Details	Funder
Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa	Sheetal P. Silal	https://www.medrxiv.org/content/10.1101/2021.12.19.21268038v1	Bill and Melinda Gates Foundation (BMGF)
Investment case for malaria elimination in South Africa: a financing model for resource mobilization to accelerate regional malaria elimination	Sheetal P. Silal	Malaria Journal volume 20, Article number: 344 (2021), https://malariajournal.biomedcentral.com/articles/10.1186/s12936-021-03875-z	BMGF
Recommended reporting items for epidemic forecasting and prediction research: The EPIFORGE 2020 guidelines	Sheetal P. Silal	PLoS Med. 2021 Oct; 18(10): e1003793.	BMGF



BILL & MELINDA
GATES *foundation*

Health Economics and Epidemiology Research Office (HE^2RO), University of Witwatersrand and Gates Foundation



HE^2RO is working at the intersection of health economics and epidemiology to find solutions to South Africa's most pressing public health challenges.

Scenarios for a Potential Fourth Wave of COVID-19 Cases for South Africa- New SACMC Report

Funders

BILL & MELINDA
GATES *foundation*



U.S President's Emergency Plan for AIDS Relief (PEPFAR), Funds the South African HIV Investment Case Study, Thusa-Thuso WHO Universal Test and Treat (UTT) policy etc



United States Agency for International Development, US government agency, which funds the HE^2RO Innovations Research on AIDS (INROADS) program



National Institutes of Health, USA funds Investigating the Feasibility of Implementation of Multi-Disciplinary Point-of-Care Testing in an HIV Treatment Clinic Using a Randomised Controlled Trial



Centre for Disease Control and Prevention, USA funds the NHLS National HIV Cohort Study



Grand Challenges Canada is a partnership between the Government of Canada and The Bill and Melinda Gates Foundation